

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



M AB

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, A61K 38/17, C12N 15/11, A61K 31/70, C12N 1/21, 15/62, C07K 19/00, C12Q 1/68, G01N 33/50, 33/60, C07K 16/28, G01N 33/53, A61K 39/395 // (C12N 1/21, C12R 1:19)		A1	(11) International Publication Number: WO 98/16640 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18174 (22) International Filing Date: 7 October 1997 (07.10.97) (30) Priority Data: 08/729,103 11 October 1996 (11.10.96) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/729,103 (CIP) Filed on 11 October 1996 (11.10.96) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). GOLI, Surya, K. [IN/US]; 3311 Cantamar Court, San Jose, CA 95135 (US).		(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: HUMAN REG I-GAMMA PROTEIN

```

1  M A S R S M R L L L L S C L - - - A K T G V L G D I M - - R P S C A P G 1310334
1  M A - Q T N S F F M L I S S L M F L S L S Q G Q E S Q T E L P N P R I S C P E G GI 474306
1  M T - R - N K Y E I L L S C L M V L S P S Q G Q E A E E D L P S A R I T C P E G GI 393209

34 W F Y H K S N C Y G Y F R K L R N W S D A E L E C Q S Y G N G A H L A S I L S L 1310334
40 T N A Y R S Y C Y F N E D P E T W V D A D L Y C Q N M N S G - N L V S V L T Q GI 474306
39 S N A Y S S Y C Y F M E D H L S W A E A D F C Q N M N S G - Y L V S V L S Q GI 393209

74 K E A S T I A E Y I S G Y Q R S Q P - I W I G L H D P Q K R Q Q W Q W I D G A M 1310334
79 A E G A F V A S L I K E S S T D D S N V W I G L H D P K N R R W H W S S G S L GI 474306
78 A E G N F L A S L I K E S G T A A N V W I G L H D P K N R R W H W S S G S L GI 393209

113 Y L Y R S W S G K S M G G N K H - - C A E M S S N N N F L T W S S N E C N K R Q 1310334
119 V S Y K S W D T G S P S S A N A G Y C A S L T S C S G P K K W K D E S C E K K F GI 474306
118 F L Y K S W D T G Y P N N S N R G Y C V S V T S N S G Y K K W R D N S C D A Q L GI 393209

151 E F L C K Y R P 1310334
159 S F V C K F R N GI 474306
158 S F V C K F R A GI 393209

```

(57) Abstract

The present invention provides a polynucleotide (Reg I-gamma) which identifies and encodes a human Reg I-gamma. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human Reg I-gamma. The invention also provides for the use of purified Reg I-gamma and its agonists in the production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I-gamma. Additionally, the invention provides for the use of Reg I-gamma antagonists and inhibitors, including antisense molecules to Reg I-gamma in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I-gamma. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding Reg I-gamma and anti-human Reg I-gamma antibodies which specifically binds to Reg I-gamma.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN REG I-GAMMA PROTEIN

TECHNICAL FIELD

The present invention relates to nucleic acid and amino acid sequences of a novel human Reg protein, which comprises a soluble C-type lectin. This novel human Reg protein shares
5 features with other proteins in the reg/PSP multigene family which are involved in cell growth. The present invention relates to the use of these novel sequences in the diagnosis, prevention and treatment of disease.

BACKGROUND ART

Lectins are proteins which are defined by their ability to bind carbohydrates specifically
10 and to agglutinate cells. Lectins have been shown to be involved in a wide variety of cellular functions including cell-cell and cell-matrix interactions. Lectins are widespread among plants, invertebrates and mammals.

Animal lectins have been grouped into four distinct families: 1) C-type lectins, which include selectins; 2) P-type lectins; 3) galectins (formerly termed S-type lectins or S-Lac lectins);
15 and 4) pentraxins [Barondes SH *et al.* (1994) J. Biol. Chem. 269:20807-10]. The C-type lectins bind carbohydrate ligands in a Ca^{2+} -dependent manner and are structurally related to the asialoglycoprotein receptor. Selectins, a subcategory of the C-type lectins, are composite transmembrane molecules which are involved in cell-cell interactions. The selectins include lymphocyte homing receptors and platelet/endothelial cell surface receptors [Stoolman (1989)
20 Cell 56:907-10].

C-type animal lectins contain Ca^{2+} -dependent carbohydrate-recognition domains (CRDs). The prototypical C-type animal lectins are integral membrane proteins (*e.g.*, the asialoglycoprotein receptor); however, a number of soluble C-type animal lectins have been identified. One group of soluble C-type animal lectins, termed collectins or Group III C-type
25 lectins, comprise proteins having both lectin- (*i.e.*, CRD) and collagenous-like domains within a single polypeptide [Drickamer (1993) Curr. Opin. Struct. Biol. 3:393]. Another group of soluble C-type animal lectins, termed Group IV C-type lectins, comprise free CRDs which are not joined to other polypeptide domains (other than a signal peptide utilized in secretion) [Drickamer (1993), *supra*]. The soluble C-type animal lectins comprising free CRDs found in mammals are
30 most closely related to proteins identified in invertebrates and lower vertebrates (*e.g.*, snakes).

Proteins recognized as members of the Group IV C-type lectins appear to be members of a multigene family termed the reg/PSP multigene family [Drickamer (1993), *supra* and Unno *et*

al. (1993) *J. Biol. Chem.* 268:15974]. The reg/PSP multigene family comprises genes encoding secretory proteins which are expressed in the pancreas; the ectopic expression (*i.e.*, expression in a tissue which does not normally express reg/PSP proteins) of some members of the reg/PSP family is associated with disease states such as tumors and Alzheimer's disease.

5 The first member of the reg/PSP multigene family was identified in a cDNA library derived from rat regenerating pancreatic islets [Terazono *et al.* (1988) *J. Biol. Chem.* 263:2111]. This gene was termed reg (*regenerating* gene) and is now known as the regI α gene; homologs of the rat regI α gene have been identified in humans [Watanabe *et al.* (1990) *J. Biol. Chem.* 265:7432] and mice [Unno *et al.* (1993), *supra*]. The regI α gene encodes a 166 amino acid
10 protein including a 22 amino acid signal peptide which has been called by different investigators reg protein, regI α protein, lithostathine, islet cell regeneration factor (ICRF), pancreatic stone protein (PSP) and pancreatic thread protein (PTP) [Terazono *et al.* (1988), *supra*; Moriizumi *et al.* (1994) *Biochem. Biophys. Acta* 1217:199; Dusetti *et al.* (1993) *Biochem. Biophys. Acta* 1174:99; Rouquier *et al.* (1991) *J. Biol. Chem.* 266:786; and de la Monte *et al.* (1990) *J. Clin. Invest.* 86:1004]. The mature form of the regI α /lithostathine protein lacks not only the signal peptide but an additional 11 amino-terminal amino acids which are removed by cleavage by
15 trypsin in pancreatic juice [Giogri *et al.* (1989) *J. Clin. Invest.* 84:100 and Rouimi *et al.* (1987) *FEBS Lett.* 216:195].

RegI α mRNA is expressed in normal human tissues most abundantly in the pancreas with
20 moderate expression seen in the gastric mucosa and very low levels of expression in the kidney [Watanabe *et al.* (1990) *J. Biol. Chem.* 265:7432]. In the pancreas, regI α protein is expressed at high levels in normal exocrine pancreas cells. No or very low levels of expression are seen in normal islet cells; in contrast, expression of regI α /lithostathine protein is increased dramatically in regenerating islet cells as compared to normal islet cells [Francis *et al.* (1992) *Diabetologia*
25 35:238]. The clear association between *reg* gene expression and islet cell replication *in vitro* has lead to the suggestion that the regI α /lithostathine protein has a growth-promoting activity for islet β -cells [Unno *et al.* (1993), *supra*].

The regI α /lithostathine protein has been shown to control CaCO₃ crystal growth in pancreatic juice [Bernard *et al.* (1992) *Gastroenterol.* 99:900]. RegI α /lithostathine protein
30 accounts for up to 10% of total protein in pancreatic juice and is present in the pancreatic juice of a variety of mammals including humans, cows, pigs, dogs, rats, and monkeys [Bernard *et al.* (1991) *Pancreas* 6:162]. Pancreatic juice is normally supersaturated with bicarbonate and

calcium which leads to the formation of CaCO_3 crystals. RegI α /lithostathine controls the size of the crystals thereby preventing clogging of pancreatic ducts; a amino-terminal undecapeptide is released from the human reg/lithostathine protein by treatment with trypsin has been shown to contain the inhibitory activity of this protein on CaCO_3 crystal growth [Bernard *et al.* (1992) 5 Gastroenterol. 103:1277]. Patients with chronic calcifying pancreatitis exhibit a reduction in regI α gene expression [Giorgi *et al.* (1989) J. Clin. Invest. 84:100].

Human regI α mRNA is expressed in colon and rectal tumors although it is not expressed in normal colon or rectal tissue. Thus, ectopic expression of regI α protein is associated with tumorigenesis. Elevated levels of regI α protein has been found in the brains of patients suffering 10 from Alzheimer's disease as well as in the brains of middle-aged individuals with Down's syndrome [Ozturk *et al.* (1989) Proc. Natl. Acad. Sci. USA 86:419 and de la Monte *et al.* (1990) J. Clin. Invest. 86:1004]. RegI α mRNA is expressed in the developing human brain, but not in normal adult brain; expression of regI α is seen in adult brain which undergoing regenerative sprouting. Given its pattern of expression (*e.g.*, expression in regenerating pancreatic islets and 15 brain, expression in tumors), it appears that regI α protein is associated with cell growth.

A gene closely related to the regI α gene, called regI β , has been identified in humans [Moriizumi *et al.* (1994) Biochem. Biophys. Acta 1217:199]. RegI β mRNA is appears to be expressed exclusively in the pancreas in contrast to regI α mRNA is expressed in stomach and kidney, as well as in pancreas. The regI β protein contains 166 amino acids and has a 22 amino 20 acid signal sequence. The regI α and regI β proteins are 87% identical in amino acid sequence; the regI α and regI β genes share 91% homology over their respective coding regions.

Other members of the reg/PSP multigene family are the genes encoding pancreatitis-associated proteins (PAPs) which have been identified in humans, mice and rats [Iovanna *et al.* (1991) J. Biol. Chem. 266:24664; Orelle *et al.* (1992) J. Clin. Invest. 90:2284; Itoh and Teraoka 25 (1993) Biochem. Biophys. Acta 1172:184; and Duseti *et al.* (1994) Genomics 19:108]. The reg/lithostathine and PAP proteins characterized to date share about 45-65% identity on the amino acid level.

The PAP proteins are secretory proteins which are stored in zymogen granules prior to secretion [Keim *et al.* (1991) Gastroenterol. 100:775]; PAP is present at low levels in normal 30 pancreas but is rapidly overexpressed during the acute phase of pancreatitis. PAP, like other members of the reg/PSP family, shares sequence similarity with the carbohydrate-binding domain of C-type lectins which likely explains the ability of PAP to induce aggregation of bacteria

[Iovanna *et al.* (1991), *supra*]. The ability to aggregate bacteria has lead to the suggestion that PAP is involved in the control of bacterial proliferation, a frequent complication of pancreatitis. PAP has been shown to be able to bind lactose [Christa *et al.* (1994) FEBS Lett. 337:114].

Three PAP genes, PAP I-III, have been identified in rats. All three PAP genes are
5 expressed during the acute phase of pancreatitis. Rat PAP I and PAP III are expressed constitutively in the intestine and their expression is induced by feeding. Rat PAP II is not expressed in the intestine. Rat PAP I and PAP III share 66% amino acid identity; rat PAP II and PAP III share 63% amino acid identity; rat PAP I and PAP II share 58% amino acid identity. A
homologue of rat PAP I has been identified in cows [BPTP; de la Monte *et al.* (1990), *supra*].

10 A human homolog of the rat PAP I gene, human PAP or human PAP I, has been identified [Orelle *et al.* (1992) J. Clin. Invest. 90:2284]. The human PAP I protein is the same size as the rat PAP I protein (175 amino acids) and these two proteins share 71% amino acid identity, including conservation of 7 cystine residues. Expression of the human PAP I mRNA is increased in necrohemorrhagic pancreatitis. Serum levels of human PAP I were found to be near
15 background levels in normal individuals; in individuals suffering from acute pancreatitis or acute exacerbations of chronic pancreatitis, human PAP I levels increased 24-140 times the background level [Orelle *et al.* (1992), *supra*]. Thus, human PAP I appears to serve as a marker of acute pancreatitis.

The human PAP I gene is also referred to as the HIP gene [Lasserre *et al.* (1992) Cancer
20 Res. 52:5089]. The HIP gene was identified by differential screening of a human primary liver cancer library. The human PAP I/HIP gene is not expressed in normal adult or fetal liver; expression of PAP I/HIP is limited to pancreas and small intestine in normal tissues. Thus, the ectopic expression of PAP I/HIP is associated with tumorigenesis in the liver.

Proteins expressed by the reg/PSP multigene family represent an important family of
25 proteins which are involved in maintenance of proper pancreatic function as well as in regulating cell growth. Discovery of new molecules related to or in the mammalian reg/PSP multigene family is useful for the development of new diagnostic or therapeutic compositions.

DISCLOSURE OF THE INVENTION

The present invention discloses a novel human reg protein hereinafter referred to as Reg
30 protein I γ (Reg I γ), which shares features with human reg proteins I α and I β (Reg I α and Reg I β) and rat lithostathine as well as other members of the reg/PSP multigene family which are involved in maintenance of proper pancreatic function as well as the regulation of cell growth and

development, including metastatic potential. Accordingly, the invention provides a substantially polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. In an alternative embodiment, the present invention provides fragments of isolated (*i.e.*, substantially purified) human Reg I γ of at least 10 amino acid residues in length. The invention further
5 contemplates fragments of isolated human Reg I γ of at least 25 amino acids, of at least 50 amino acids, at least 100 amino acids, and at least 150 amino acids in length. The invention specifically contemplates secretory (*i.e.*, the signal peptide is cleaved) and nonsecretory (*i.e.*, signal peptide remains) forms of a substantially purified human Reg I γ as well as any proteolytic fragments thereof.

10 The present invention further provides an isolated polynucleotide sequence encoding a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. In a preferred embodiment, the isolated polynucleotide comprises at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof. In another preferred embodiment, the present invention provides polynucleotides comprising fragments of SEQ ID NO:2 having a length
15 greater than 30 nucleotides. The invention further contemplates fragments of this polynucleotide sequence (*i.e.*, SEQ ID NO:2) that are at least 50 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. The invention specifically contemplates polynucleotides encoding the secretory (*i.e.*, the signal peptide is cleaved) and nonsecretory (*i.e.*, signal peptide remains) forms of human Reg I γ as well as any proteolytic fragments thereof.

20 In yet another embodiment, the present invention provides polynucleotide sequences comprising the complement of the nucleic acid sequence of SEQ ID NO:2 or variants thereof; these complementary nucleic acid sequences may comprise the complement of the entire nucleic acid sequence of SEQ ID NO:2 or fragments thereof.

In another embodiment, the present invention provides a polynucleotide sequence that
25 hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO:2.

The invention further relates to the nucleic acid sequence encoding human Reg I γ , oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof.

The present invention also provides a method for detecting the presence of polynucleotide
30 sequences encoding at least a portion of human Reg I γ in a biological sample, comprising the steps of: a) providing: i) a biological sample suspected of containing nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2; ii) the polynucleotide of SEQ ID NO:2, or a

fragment thereof; b) combining the biological sample with the polynucleotide under conditions such that a hybridization complex is formed between the nucleic acid and the polynucleotide; and c) detecting the hybridization complex. The method of the present invention is not limited by the nature of the nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2. In a preferred embodiment, the nucleic acid is ribonucleic acid (RNA) and the detection of a hybridization complex between SEQ ID NO:2 and the RNA correlates with expression of the polynucleotide of SEQ ID NO:2 in the biological sample. In another preferred embodiment, the nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2 is deoxyribonucleic acid (DNA) and the detection of a hybridization complex between the DNA in a sample and SEQ ID NO:2 is performed under conditions that permit the detection of alterations (e.g., deletions, translocations, insertions, point mutations, etc.) in the polynucleotide of SEQ ID NO:2 in the biological sample.

The present invention further provides an antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2. In another embodiment, the present invention provides a pharmaceutical composition comprising an antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2 and a pharmaceutically acceptable excipient.

In another embodiment, the present invention provides an isolated polynucleotide comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof contained on a recombinant expression vector. In yet another embodiment, the expression vector containing the polynucleotide sequence is contained within a host cell. The invention is not limited by the nature of the host cell employed. For example, the host cell may be an *E. coli* cell, a yeast cell, an insect cell, a mammalian cell, etc.

The present invention further provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, the method comprising the steps of: a) culturing the host cell containing an expression vector containing an isolated polynucleotide comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

In another embodiment, the present invention provides a pharmaceutical composition comprising a substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

The present invention also provides a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. The present invention further provides a pharmaceutical composition comprising a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid
5 sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

The present invention also provides a method for detecting the expression of human Reg I γ in a biological sample comprising the steps of: a) providing: i) a biological sample suspected of expressing human Reg I γ protein; and ii) a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1; b)
10 combining the biological sample and the antibody under conditions such that an antibody:protein complex is formed; and c) detecting the complex wherein the presence of the complex correlates with the expression of the protein in the biological sample.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the amino acid sequence (SEQ ID NO:1) and nucleic acid
15 sequence (SEQ ID NO:2) of human Reg I γ . The alignment was produced using MacDNAsis™ software (Hitachi Software Engineering Co Ltd, San Bruno, CA).

Figure 2 shows the amino acid sequence alignment between human Reg I γ (SEQ ID NO:1), human Reg I β [GI 474306 (SEQ ID NO:3); Moriizumi *et al.* (1994), *supra*] and rat Reg/lithostathine [GI 393209 (SEQ ID NO:4); Duseti *et al.* (1993), *supra*]. These alignments
20 were produced using the multisequence alignment program of DNASTar™ software (DNASTar Inc, Madison WI).

Figure 3 shows the northern analysis for Incyte Clone 1310334 (SEQ ID NO:2). The northern analysis was produced electronically using the LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto, CA) and shows cDNA libraries in which sequences encoding human
25 Reg I γ were expressed.

Figure 4 shows the hydrophobicity plot for human Reg I γ , SEQ ID NO:1, generated using MacDNAsis software; the X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

Figure 5 shows the isoelectric plot for human Reg I γ , SEQ ID NO:1, generated using
30 MacDNAsis software.

Figure 6 shows the secondary structure for the human Reg I γ , SEQ ID NO:1, generated using MacDNAsis software.

MODES FOR CARRYING OUT THE INVENTION

Definitions

To facilitate understanding of the invention, a number of terms are defined below.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or
5 polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic
origin which may be single- or double-stranded, and represent the sense or antisense strand.
Similarly, "amino acid sequence" as used herein refers to peptide or protein sequence.

"Consensus" as used herein may refer to a nucleic acid sequence 1) which has been
resequenced to resolve uncalled bases, 2) which has been extended using XL-PCR (Perkin Elmer,
10 Norwalk CT) in the 5' or the 3' direction and resequenced, 3) which has been assembled from
the overlapping sequences of more than one Incyte clone GCG Fragment Assembly System,
(GCG, Madison WI), or 4) which has been both extended and assembled.

"Peptide nucleic acid" ("PNA") as used herein refers to a molecule which comprises an
oligomer to which an amino acid residue, such as lysine, and an amino group have been added.
15 These small molecules, also designated anti-gene agents, stop transcript elongation by binding to
their complementary strand of nucleic acid [Nielsen PE *et al.* (1993) *Anticancer Drug Des*
8:53-63].

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which
one or more nucleotides or amino acid residues, respectively, are absent.

20 An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which
has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as
compared to, for example, the naturally occurring human Reg I γ .

A "substitution" results from the replacement of one or more nucleotides or amino acids
by different nucleotides or amino acids, respectively.

25 As used herein the "reg/PSP multigene family" refers to genes encoding any of the
following proteins: regenerating protein, reg protein, regI α protein, regI β , lithostathine, islet cell
regeneration factor (ICRF), pancreatic stone protein (PSP), pancreatic thread protein (PTP), HIP
protein, pancreatitis-associated protein (PAP) and the novel Reg I γ of the present invention, as
well as other genes which encode proteins sharing at least 21% identity with the listed proteins.
30 Members of the reg/PSP multigene family share a number of features including expression in the
pancreas and the presence of sequences conserved among the CRD of C-type lectins. On the
amino acid level, members of the reg/PSP multigene family share about 30-87% identity. Protein

sequences comprising typical amino acid compositions (*i.e.*, amino acids are present at their observed normal frequencies) which share an identity of greater than 20% are defined as "homologous" or related proteins; this assumes that only a limited number of insertions and deletions are made to align the sequences being compared [Creighton, *Proteins, Structure and Molecular Properties*, 2nd ed., W.H. Freeman, NY, pp. 108-109 (1993)].

As used herein, "Reg I γ " or "Reg protein I γ " refers to the amino acid sequence of substantially purified Reg I γ obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic or recombinant.

10 A "variant" of Reg I γ is defined as an amino acid sequence differs by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, *e.g.*, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, *e.g.*, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (*i.e.*,
15 additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTar software. Furthermore, as described herein, certain amino acid residues which are highly conserved among mammalian Reg and PAP proteins are located within the CRD of these C-type lectins. It is
20 preferred that these conserved residues not be substituted, inserted or deleted when producing variants of human Reg I γ .

The term "biologically active" refers to a Reg I γ molecule having structural, regulatory or biochemical functions of a naturally occurring Reg I γ . Likewise, "immunologically active" defines the capability of the natural, recombinant or synthetic Reg I γ , or any oligopeptide
25 thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "derivative" as used herein refers to the chemical modification of a nucleic acid encoding Reg I γ or the encoded Reg I γ . Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a
30 polypeptide which retains essential biological characteristics of natural human Reg I γ .

As used herein, the term "substantially purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated,

and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. An "isolated polynucleotide" is therefore a substantially purified polynucleotide.

"Amplification" is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction technologies well known in the art [Dieffenbach CW and GS Dveksler (1995) *PCR Primer, a Laboratory Manual*, Cold Spring Harbor Press, Plainview NY].

The term "hybridization" as used herein refers to any process by which a strand of nucleic acid joins with a complementary strand through base pairing.

As used herein the term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (*e.g.*, C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid support [*e.g.*, a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in *in situ* hybridization, including FISH (fluorescent *in situ* hybridization)].

As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (*i.e.*, a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence "A-G-T," is complementary to the sequence "T-C-A." Complementarity may be "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.

The term "homology" when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely

complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

Low stringency conditions comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄•H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

High stringency conditions comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄•H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

The art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions. The term "hybridization" as used herein includes "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" [Coombs J (1994) *Dictionary of Biotechnology*, Stockton Press, New York NY].

"Stringency" typically occurs in a range from about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. Under "stringent conditions" SEQ ID NO:2 or fragments thereof will hybridize to its exact complement and closely related sequences. The stringent conditions are chosen such that SEQ ID NO:2 or fragments thereof will hybridize to sequences encoding human Reg I γ but not to sequences encoding human Reg I β (*i.e.*, SEQ ID NO:3 or its RNA equivalents) or rat Reg/lithostathine (*i.e.*, SEQ ID NO:4 or its RNA equivalents). When fragments of SEQ ID NO:2 are employed in hybridization reactions, the stringent conditions include the choice of fragments of SEQ ID NO:2 to be used. Fragments of SEQ ID NO:2 which contain unique sequences (*i.e.*, regions which are either non-homologous to or which contain less than about 50% homology or complementarity with SEQ ID NOS:5 or 6) are preferentially employed. SEQ ID NOS:5 and 6 represent DNA sequences encoding the human regI β and rat reg/lithostathine proteins, respectively.

As used herein, the term "antisense" is used in reference to RNA sequences which are complementary to a specific RNA sequence (*e.g.*, mRNA). Antisense RNA may be produced by any method, including synthesis by splicing the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a coding strand. Once introduced into a cell, this transcribed strand combines with natural mRNA produced by the cell to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation. In this manner, mutant phenotypes may be generated. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. The designation (-) (*i.e.*, "negative") is sometimes used in reference to the antisense strand, with the designation (+) sometimes used in reference to the sense (*i.e.*, "positive") strand.

As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:2" encompasses the full-length human Reg I γ protein and fragments thereof.

The term "antigenic determinant" as used herein refers to that portion of a molecule that makes contact with a particular antibody (*i.e.*, an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the

production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (*i.e.*, the immunogen used to elicit the immune response) for binding to an antibody.

5 The terms "specific binding" or specifically binding" when used in reference to the interaction of an antibody and a protein or peptide means that the interaction is dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the protein; in other words the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a
10 protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample" as used herein is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding human Reg I γ may comprise a cell, chromosomes isolated from a cell (*e.g.*, a spread of metaphase chromosomes), genomic DNA (in solution or
15 bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for Northern blot analysis), cDNA (in solution or bound to a solid support) and the like. A sample suspected of containing a protein may comprise a cell, a portion of a tissue, an extract containing one or more proteins and the like.

The term "correlates with expression of a polynucleotide" as used herein indicates that the
20 detection of the presence of ribonucleic acid complementary to SEQ ID NO:2 by hybridization assays is indicative of the presence of mRNA encoding human Reg I γ in a sample and thereby correlates with expression of the Reg I γ mRNA from the gene encoding Reg I γ .

"Alterations in the polynucleotide of SEQ ID NO:2" as used herein comprise any alteration in the sequence of polynucleotides encoding human Reg I γ including deletions,
25 insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes human Reg I γ [*e.g.*, by alterations in pattern of restriction enzyme fragments capable of hybridizing to SEQ ID NO:2 (RFLP analysis), the inability of a selected fragment of SEQ ID NO:2 to hybridize to a sample of genomic DNA (*e.g.*, using allele-specific oligonucleotide probes), improper or
30 unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the *reg I γ* gene (*e.g.*, using FISH to metaphase chromosomes spreads, etc.)].

Preferred Embodiments

Given the role C-type lectins play in regulating cell growth and development, the discovery of new molecules related to or in the C-type lectin gene family, and in the human reg/PSP multigene family in particular, is useful for developing diagnostic or therapeutic compositions directed at detecting or preventing neoplasia and/or metastasis. In addition, overexpression of Reg proteins is seen in Alzheimer's disease and thus novel human *reg* genes are useful for developing diagnostic or therapeutic compositions directed at detection and treatment of the neurodegenerative changes associated with Alzheimer's disease and other disorders of the central nervous system (*e.g.*, Down's syndrome).

As aberrant (*e.g.*, ectopic) expression of members within the reg/PSP gene family is associated with tumorigenesis, the discovery of new molecules related to or in the reg/PSP gene family is useful for developing diagnostic or therapeutic compositions directed at a variety of tumors. Furthermore, new molecules related to or in the reg/PSP gene family are useful for developing diagnostic or therapeutic compositions directed at correcting diseases associated with the overexpression or underexpression of reg/PSP proteins.

The present invention relates to a novel human Reg I γ which was initially identified among the partial cDNAs from a fetal colon library (COLNFET02) and to the use of the disclosed nucleic acid and amino acid sequences in the study, diagnosis, prevention and treatment of disease.

The nucleic acid sequence encoding a portion of the novel human Reg I γ protein was identified in Incyte Clone 1310334 through a computer-generated search for amino acid sequence alignments. The nucleic acid sequence, SEQ ID NO:2, disclosed herein, encodes the amino acid sequence, SEQ ID NO:1, human Reg I γ (Figure 2). The full length cDNA was assembled from Incyte Clones 774137; 775162; 793926; 794035; 794837; 794931; 798309; 815300; 816795; 817375; 1310334; and 1436720 from the LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto, CA).

The human Reg I γ of the present invention is here described as having 158 amino acid residues, a number of which are residues shown to be conserved among mammalian Reg and PAP proteins and which are conserved among the CRD of C-type animal lectins. The conserved sequence motif found in C-type CRDs is described by Drickamer [Curr. Opin. Struc. Biol. (1993) 3:393] and a version of this motif is found in the PROSITE database as the C-type lectin domain

signature (CTL). Sequences corresponding to the CTL within the human Reg I γ of the present invention include G₃₃, C₅₈, G₉₅, D₉₈, W₁₁₈, C₁₂₉, A₁₃₀, W₁₄₁, C₁₄₆, F₁₅₂ and C₁₅₄.

The amino-terminal 23 residues of the human Reg I γ of the present invention are hydrophobic and likely represent a signal sequence, a feature common to mammalian Reg and

5 PAP proteins.

The human Reg I γ of the present invention contains seven cysteine residues (C₁₄, C₃₀, C₄₁, C₅₈, C₁₂₉, C₁₄₆ and C₁₅₄); six of these seven cysteine residues (*i.e.*, C₃₀, C₄₁, C₅₈, C₁₂₉, C₁₄₆ and C₁₅₄) are conserved between the human Reg I γ and RegI β and rat Reg/lithostathine proteins (see alignment shown in Figure 2; residues are numbered according to SEQ ID NO:1). The human
10 Reg I γ of the present invention has one potential N-linked glycosylation sites (*i.e.*, Asn-X-Ser/Thr) (*i.e.*, N₅₀). The human Reg I γ of the present invention contains numerous potential O-linked glycosylation sites (*i.e.*, serine and threonine residues). Other human Reg proteins have been shown to be glycosylated [Watanabe *et al.* (1990), *supra*]. In addition, the human Reg I γ of the present invention contains potential phosphorylation sites (*i.e.*, typically the hydroxyl groups
15 of serine, threonine and tyrosine residues although asparagine, histidine and lysine residues may also be phosphorylated). Serine residues preceded by one or two basic residues are often phosphorylated by Ser/Thr kinases [Creighton, *Proteins, Structure and Molecular Properties*, 2nd ed., W.H. Freeman, NY, pp. 96-97 (1993)]; the novel human Reg I γ protein disclosed herein contains four such potential phosphorylation sites (*i.e.*, S₃₉, S₈₉, S₁₁₇, and S₁₂₂). Other human Reg
20 proteins (*e.g.*, human reg/lithostathine/PSP) have been shown to be phosphoglycoproteins containing two to three phosphate groups [Multigener *et al.* (1985) *Gastroenterology* 89:387].

The Human Reg I γ Coding Sequences

The nucleic acid and deduced amino acid sequences of human Reg I γ are shown in Figures 1A and 1B. In accordance with the invention, any nucleic acid sequence which encodes
25 human Reg I γ can be used to generate recombinant molecules which express human Reg I γ . In a specific embodiment described herein, a partial sequence encoding human Reg I γ was first isolated as Incyte Clone 1310334 from a fetal colon cDNA library (COLNFET02).

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of human Reg I γ -encoding nucleotide sequences, some bearing
30 minimal homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These

combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence encoding naturally occurring human Reg I γ , and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode human Reg I γ and its variants are
5 preferably capable of hybridizing to the nucleotide sequence of the naturally occurring sequence under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding human Reg I γ or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the
10 frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding human Reg I γ and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater or a shorter half-life, than transcripts produced from the naturally occurring sequence.

15 It is now possible to produce a DNA sequence, or portions thereof, encoding human Reg I γ and its derivatives entirely by synthetic chemistry, after which the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding human Reg I γ or any portion thereof.

20 Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of Figure 1B under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (1987, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol 152, Academic Press, San Diego CA)
25 incorporated herein by reference, and may be used at a defined "stringency".

Altered nucleic acid sequences encoding human Reg I γ which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent human Reg I γ . The protein may also show deletions, insertions or substitutions of amino acid residues which produce
30 a silent change and result in a functionally equivalent human Reg I γ . Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the

biological activity of human Reg I γ is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine
5 phenylalanine, and tyrosine.

Included within the scope of the present invention are alleles encoding human Reg I γ . As used herein, an "allele" or "allelic sequence" is an alternative form of the nucleic acid sequence encoding human Reg I γ . Alleles result from a mutation, *i.e.*, a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may
10 or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing are well known in the art and employ such enzymes as the
15 Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH), *Taq* DNA polymerase (Perkin Elmer, Norwalk CT), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200
20 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer).

Extending The Polynucleotide Sequence

The polynucleotide sequence encoding human Reg I γ may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as
25 promoters and regulatory elements. Gobinda *et al.* (1993; PCR Methods Applic 2:318-22) describe "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker
30 primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia T *et al.* (1988) *Nucleic Acids Res* 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom M *et al.* (1991) *PCR Methods Applic* 1:111-19), a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA, may also be used. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

Another method which may be used to retrieve unknown sequence is walking PCR (Parker JD *et al.* (1991) *Nucleic Acids Res* 19:3055-60), a method for targeted gene walking. Alternatively, PCR, nested primers, PromoterFinder™ (Clontech, Palo Alto CA) and PromoterFinder libraries can be used to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

Capillary electrophoresis may be used to analyze either the size or confirm the nucleotide sequence in sequencing or PCR products. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (*e.g.*, Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small

pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp of M13 phage DNA in 30 min has been reported [Ruiz-Martinez MC *et al.* (1993) Anal Chem 65:2851-8].

Expression Of The Nucleotide Sequence

5 In accordance with the present invention, polynucleotide sequences which encode human Reg I γ , fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of human Reg I γ in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to
10 clone and express human Reg I γ . As will be understood by those of skill in the art, it may be advantageous to produce human Reg I γ -encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host [Murray E *et al.* (1989) Nuc Acids Res 17:477-508] can be selected, for example, to increase the rate of human Reg I γ expression or to produce recombinant RNA transcripts having desirable properties, such
15 as a longer or a shorter half-life, than transcripts produced from naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered in order to alter a human Reg I γ -encoding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, *e.g.*,
20 site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc.

In another embodiment of the invention, a natural, modified or recombinant human Reg I γ -encoding sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of human Reg I γ activity, it may be
25 useful to encode a chimeric human Reg I γ protein that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a human Reg I γ and the heterologous protein sequence, so that the human Reg I γ may be cleaved and substantially purified away from the heterologous moiety.

In an alternate embodiment of the invention, the sequence encoding human Reg I γ may
30 be synthesized, whole or in part, using chemical methods well known in the art [see Caruthers MH *et al.* (1980) Nuc Acids Res Symp Ser 215-23, Horn T *et al.* (1980) Nuc Acids Res Symp Ser 225-32, etc.]. Alternatively, the protein itself could be produced using chemical methods to

synthesize a human Reg I γ amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques [Roberge JY *et al.* (1995) Science 269:202-204] and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the
5 manufacturer.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography [*e.g.*, Creighton (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co, New York NY]. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure;
10 Creighton, *supra*). Additionally the amino acid sequence of human Reg I γ , or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

Expression Systems

In order to express a biologically active human Reg I γ , the nucleotide sequence encoding
15 human Reg I γ or its functional equivalent, is inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing a human Reg I γ -encoding sequence and appropriate transcriptional
20 or translational controls. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination or genetic recombination. Such techniques are described in Sambrook *et al.* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview NY and Ausubel FM *et al.* (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY.

25 A variety of expression vector/host systems may be utilized to contain and express a human Reg I γ -encoding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transfected with virus expression vectors
30 (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmid); or animal cell systems.

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3' and 5' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla CA) or pSport1 (Gibco BRL) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO; and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding human Reg I γ , vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for human Reg I γ . For example, when large quantities of human Reg I γ are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding human Reg I γ may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors [Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509]; and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel *et al.* (*supra*) and Grant *et al.* (1987) Methods in Enzymology 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding human Reg I γ may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV [Brisson *et al.* (1984) *Nature* 310:511-514] may be used alone or in combination with the omega leader sequence from TMV [Takamatsu *et al.* 5 (1987) *EMBO J* 6:307-311]. Alternatively, plant promoters such as the small subunit of RUBISCO [Coruzzi *et al.* (1984) *EMBO J* 3:1671-1680; Broglie *et al.* (1984) *Science* 224:838-843]; or heat shock promoters [Winter J and Sinibaldi RM (1991) *Results Probl Cell Differ* 17:85-105] may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see 10 Hobbs S or Murry LE in *McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill New York NY, pp 191-196 or Weissbach and Weissbach (1988) *Methods for Plant Molecular Biology*, Academic Press, New York NY, pp 421-463.

An alternative expression system which could be used to express human Reg I γ is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) 15 is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequence encoding human Reg I γ may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the sequence encoding human Reg I γ will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses are then 20 used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which human Reg I γ is expressed [Smith *et al.* (1983) *J Virol* 46:584; Engelhard EK *et al.* (1994) *Proc Natl Acad Sci* 91:3224-7].

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a sequence encoding human Reg I γ may be ligated into an adenovirus transcription/ translation complex consisting of the late 25 promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing in infected host cells [Logan and Shenk (1984) *Proc Natl Acad Sci* 81:3655-59]. In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a sequence 30 encoding human Reg I γ . These signals include the ATG initiation codon and adjacent sequences. In cases where the sequence encoding human Reg I γ , its initiation codon and upstream sequences are inserted into the most appropriate expression vector, no additional

translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon, and termination codons must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure translation of the entire insert. Exogenous translational
5 elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use [Scharf D *et al.* (1994) *Results Probl Cell Differ* 20:125-62; Bittner *et al.* (1987) *Methods in Enzymol* 153:516-544].

In addition, a host cell strain may be chosen for its ability to modulate the expression of
10 the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO (ATCC CCL 61 and CRL 9618), HeLa (ATCC CCL
15 2), MDCK (ATCC CCL 34 and CRL 6253), HEK 293 (ATCC CRL 1573), WI-38 (ATCC CCL 75) (ATCC: American Type Culture Collection, Rockville, MD), etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is
20 preferred. For example, cell lines which stably express human Reg I γ may be transformed using expression vectors which contain endogenous expression elements, and may also contain viral origins of replication and a selectable marker gene; the selectable marker gene may be located on the same vector as the Reg I γ -encoding sequences or may be located on a separate vector which contains sequences which permit expression of the selectable marker gene. Following the
25 introduction of the vector(s), cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transfected cells can be proliferated using tissue culture techniques appropriate to the cell type.

30 Any number of selection systems may be used to recover transfected cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy I *et al.* (1980) *Cell* 22:817-23)

genes which can be employed in tk- or apt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate [Wigler M *et al.* (1980) Proc Natl Acad Sci 77:3567-70]; *npt*, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin F *et al.* (1981) J Mol Biol 150:1-14] and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine [Hartman SC and RC Mulligan (1988) Proc Natl Acad Sci 85:8047-51]. Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes CA *et al.* (1995) Methods Mol Biol 55:121-131].

Identification Of Transformants Containing The Polynucleotide Sequence

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the sequence encoding human Reg Iy is inserted within a marker gene sequence, recombinant cells containing the sequence encoding human Reg Iy can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence encoding human Reg Iy under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem sequence as well.

Alternatively, host cells which contain the coding sequence for human Reg Iy and express human Reg Iy may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding human Reg Iy can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the sequence encoding human Reg Iy. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the nucleic acid sequence to detect transformants containing DNA or RNA encoding human Reg Iy. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about

60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplicon.

A variety of protocols for detecting and measuring the expression of human Reg I γ , using either polyclonal or monoclonal antibodies specific for the protein are known in the art.

- 5 Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on human Reg I γ is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R *et al.* (1990, *Serological Methods a Laboratory Manual*, APS Press,
10 St Paul MN) and Maddox DE *et al.* (1983, *J Exp Med* 158:1211).

- A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the
15 human Reg I γ -encoding sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

- A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison
20 WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like.

Purification Of Human Reg I γ

- 25 Host cells transformed with a nucleotide sequence encoding human Reg I γ may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing human Reg I γ -encoding sequence can be
30 designed with signal sequences which direct secretion of human Reg I γ through a prokaryotic or eukaryotic cell membrane; the naturally occurring Reg I γ signal sequence may be utilized or alternatively, heterologous signal sequences derived from prokaryotic or eukaryotic genes may be

employed. Further, the art understands that where secretion of human Reg I γ is not desired, sequences encoding the naturally-occurring human Reg I γ signal sequence are not employed on expression vectors containing human Reg I γ gene sequences.

Human Reg I γ may also be expressed as a recombinant protein with one or more
5 additional polypeptide domains added to facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle,
10 WA). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and human Reg I γ is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding human Reg I γ and nucleic acid sequence encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage site. The histidine residues
15 facilitate purification while the enterokinase cleavage site provides a means for purifying human Reg I γ from the fusion protein. Literature pertaining to vectors containing fusion proteins is available in the art [see, for example, Kroll DJ *et al.* (1993) DNA Cell Biol 12:441-53].

In addition to recombinant production, fragments of human Reg I γ may be produced by direct peptide synthesis using solid-phase techniques [cf Stewart *et al.* (1969) *Solid-Phase*
20 *Peptide Synthesis*, WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of human Reg I γ may be chemically
25 synthesized separately and combined using chemical methods to produce the full length molecule.

Uses Of Human Reg I γ

The rationale for use of the nucleotide and peptide sequences disclosed herein is based in part on the chemical and structural homology among the novel human Reg I γ protein and the
30 human Reg I β [GI 474306; Moriizumi *et al.* (1994), *supra*] and rat reg/lithostathine proteins [GI 393209; Dusetti *et al.* (1993), *supra*]. In addition, the novel human Reg I γ protein shares structural features with several other proteins in the reg/PSP multigene family, including amino

acid sequences which are conserved among the CRD of C-type lectins. Lectins are involved in a variety of cellular functions including cell-cell and cell-matrix interactions; aberrant expression of some lectins is associated with tumorigenesis and/or metastasis. Indeed, aberrant expression of some members of the reg/PSP multigene family is associated with a variety of disease states.

5 For example, overexpression of human regI α is observed in human colon and rectal tumors [Watanabe *et al.* (1990), *supra*]. Overexpression of human regI α is observed in the brains of Alzheimer's patients and in the brains of middle-age Down's syndrome patients [de la Monte *et al.* (1990), *supra*]. Brains from these patients show an accumulation of paired helical filaments which are similar to the filamentous bundles formed by regI α protein *in vitro* (hence some
10 investigators termed this protein pancreatic thread protein) [Gross *et al.* (1985) Proc. Natl. Acad. Sci. USA 82:5627]. Expression of the human PAP I/HIP gene in adult liver is associated with liver cancer; PAPI/HIP is not expressed in normal adult or fetal liver [Lasserre *et al.* (1992), *supra*]. PAP proteins are overexpressed in the pancreas of individuals suffering from acute pancreatitis and thus serve as markers for this disease [Orelle *et al.* (1992), *supra*].

15 Proteins within the reg/PSP multigene family are expressed in the pancreas. As demonstrated herein, the human Reg I γ of the present invention, like other reg/PSP genes, is expressed in pancreas. In addition, as shown herein, human Reg I γ is expressed most abundantly in human ovary and in ovarian tumor tissue with lower levels of expression in colon tissue. As other investigations failed to examine the expression of reg/PSP family members in ovarian
20 tissue, it is not known whether the abundant expression of human Reg I γ in the ovary is a feature unique to this novel gene or whether this is a characteristic shared by other reg/PSP family members.

Ectopic expression or the perturbations of the normal pattern of expression of reg/PSP proteins has been shown to be associated with a variety of disease states, including tumors and
25 neurodegenerative diseases; therefore, the human Reg I γ nucleic and amino acid sequences of the present invention are useful in the development of diagnostics for the detection of tumors and other diseases. The nucleotide sequence may be used in hybridization or PCR technologies to diagnose the induced expression of Reg I γ sequences early in the disease process. Likewise the protein can be used to produce antibodies useful in ELISA assays or a derivative diagnostic
30 format (as discussed in detail below).

In order to provide a basis for diagnosis, normal or standard values for human Reg I γ mRNA expression must be established. This is accomplished by quantitating the amount of Reg

I γ mRNA in tissues taken from normal subjects, either animal or human, with nucleic probes derived from the Reg I γ sequences provided herein (either DNA or RNA forms) using techniques which are well known in the art (*e.g.*, Southern blots, Northern blots, dot or slot blots). The standard values obtained from normal samples may be compared with values obtained from
5 samples from subjects potentially affected by disease (*e.g.*, tumors, Alzheimer's, chronic calcifying pancreatitis or other disorders of the pancreas). Deviation between standard and subject values establishes the presence of a disease state.

The nucleotide sequence encoding human Reg I γ is useful when placed in an expression vector for making quantities of protein for therapeutic use. The antisense nucleotide sequence of
10 the human RegI γ gene is potentially useful in vectors designed for gene therapy directed at neoplasia including metastases. Additionally, the inhibition of human Reg I γ expression may be useful in alleviating the neurodegenerative changes associated with disorders such as Alzheimer's disease. Alternatively, the human Reg I γ -encoding nucleotide sequence may be used to direct the expression of human Reg I γ in situations where it is desirable to increase the amount of human
15 Reg I γ (*e.g.*, for disorders associated with low or nonexistent level of expression of Reg I γ or to induce or aid in the regeneration of pancreatic islet cells). Even the transient expression or delivery of human Reg I γ to cells and tissues may be therapeutic. The expression of reg/PSP proteins is important for proper pancreatic function and therefore the ability to increase the level of expression of human Reg I γ in patients which fail to express normal levels of Reg I γ in the
20 pancreas is therapeutic.

Human Reg I γ Antibodies

Human Reg I γ -specific antibodies are useful for the diagnosis and treatment of conditions and diseases associated with expression of human Reg I γ (including the overexpression and the absence of expression). Such antibodies include, but are not limited to, polyclonal, monoclonal,
25 chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, *i.e.*, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics.

Human Reg I γ protein to be used for antibody induction need not retain biological activity; however, the protein fragment, or oligopeptide must be antigenic. Peptides used to
30 induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids. Preferably, they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small,

naturally occurring molecule. Short stretches of human Reg I γ amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc
5 may be immunized by injection with human Reg I γ or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and
10 dinitrophenol. BCG (Bacillus Calmette-Guerin) and *Corynebacterium parvum* are potentially useful adjuvants.

Monoclonal antibodies to human Reg I γ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and
15 Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor *et al.* (1983) Immunol Today 4:72; Cote *et al.* (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique [Cole *et al.* (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss Inc, New York NY, pp 77-96].

In addition, techniques developed for the production of "chimeric antibodies", the splicing
20 of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used [Morrison *et al.* (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger *et al.* (1984) Nature 312:604-608; Takeda *et al.* (1985) Nature 314:452-454]. Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,778) can be adapted to produce human Reg I γ -specific single chain
25 antibodies.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi *et al.* (1989, Proc Natl Acad Sci 86:3833-3837), and Winter G and Milstein C (1991; Nature 349:293-299).

30 Antibody fragments which contain specific binding sites for human Reg I γ may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments

which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity [Huse WD *et al.* (1989) Science 256:1275-1281].

A variety of protocols for competitive binding or immunoradiometric assays using either
5 polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between human Reg I γ and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific human Reg I γ protein is preferred, but a competitive binding assay may also be
10 employed. These assays are described in Maddox DE *et al.* (1983, J Exp Med 158:1211).

Diagnostic Assays Using Human Reg I γ Specific Antibodies

Particular human Reg I γ antibodies are useful for the diagnosis of conditions or diseases characterized by expression of human Reg I γ or in assays to monitor patients being treated with human Reg I γ , its fragments, agonists or inhibitors (including antisense transcripts capable of
15 reducing expression of human Reg I γ). Diagnostic assays for human Reg I γ include methods utilizing the antibody and a label to detect human Reg I γ in human body fluids or extracts of cells or tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter
20 molecules are known, several of which were described above.

A variety of protocols for measuring human Reg I γ , using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal
25 antibodies reactive to two non-interfering epitopes on human Reg I γ is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE *et al.* (1983, J Exp Med 158:1211).

In order to provide a basis for diagnosis, normal or standard values for human Reg I γ expression must be established. This is accomplished by combining body fluids or cell extracts
30 taken from normal subjects, either animal or human, with antibody to human Reg I γ under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes

containing known quantities of human Reg I γ with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease (*e.g.*, metastases, Alzheimer's disease, chronic calcifying pancreatitis or other disorders of the pancreas). Deviation
5 between standard and subject values establishes the presence of a disease state.

Drug Screening

Human Reg I γ , its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a
10 cell surface, or located intracellularly. The formation of binding complexes, between human Reg I γ and the agent being tested, may be measured.

Another technique for drug screening which may be used for high throughput screening of compounds having suitable binding affinity to the human Reg I γ is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO Application
15 84/03564, published on September 13, 1984, and incorporated herein by reference. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with fragments of human Reg I γ and washed. Bound human Reg I γ is then detected by methods well known in the art. Substantially purified human Reg I γ can also be coated directly onto plates for
20 use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding human Reg I γ specifically compete with a test compound for binding human Reg I γ . In this manner, the antibodies can be used to detect the
25 presence of any peptide which shares one or more antigenic determinants with human Reg I γ .

Uses Of The Polynucleotide Encoding Human Reg I γ

A polynucleotide sequence encoding human Reg I γ or any part thereof may be used for diagnostic and/or therapeutic purposes. For diagnostic purposes, the sequence encoding human Reg I γ of this invention may be used to detect and quantitate gene expression in biopsied tissues
30 in which human Reg I γ may be expressed. The diagnostic assay is useful to distinguish between absence, presence, and excess expression of human Reg I γ and to monitor regulation of human

Reg Iy levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs.

Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding
5 human Reg Iy or closely related molecules. The specificity of the probe, whether it is made from a highly specific region, *e.g.*, 10 unique nucleotides in the 5' regulatory region, or a less specific region, *e.g.*, especially in the 3' region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring human Reg Iy, alleles or related sequences.

10 Probes may also be used for the detection of related sequences and should preferably contain at least 50% of the nucleotides from any of these human Reg Iy-encoding sequences. The hybridization probes of the subject invention may be derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements and introns of the naturally occurring sequence encoding human Reg Iy. Hybridization probes may be
15 labeled by a variety of reporter groups, including radionuclides such as ³²P or ³⁵S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Other means for producing specific hybridization probes for DNAs include the cloning of nucleic acid sequences encoding human Reg Iy or human Reg Iy derivatives into vectors for the
20 production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

Diagnostic Use

25 Polynucleotide sequences encoding human Reg Iy may be used for the diagnosis of conditions or diseases with which the expression of human Reg Iy is associated. For example, polynucleotide sequences encoding human Reg Iy may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect human Reg Iy expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other
30 membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.

The human Reg I γ -encoding nucleotide sequences disclosed herein provide the basis for assays that detect activation or induction associated with disease (including metastasis); in addition, the lack of expression of human Reg I γ may be detected using the human Reg I γ -encoding nucleotide sequences disclosed herein. The nucleotide sequence may be labeled by
5 methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. If the amount of dye in the
10 biopsied or extracted sample is significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of elevated levels of nucleotide sequences encoding human Reg I γ in the sample indicates the presence of the associated inflammation and/or disease. Alternatively, the loss of expression of human Reg I γ sequences in a tissue which normally expresses human Reg I γ sequences indicates
15 the presence of an abnormal or disease state.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for human Reg I γ expression must be established. This is accomplished by combining body fluids or cell
20 extracts taken from normal subjects, either animal or human, with human Reg I γ , or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of human Reg I γ run in the same experiment where a known amount of substantially purified human Reg I γ is used. Standard values obtained from normal samples may be compared with
25 values obtained from samples from patients affected by human Reg I γ -associated diseases. Deviation between standard and subject values establishes the presence of disease.

Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern. Successive treatment profiles
30 may be used to show the efficacy of treatment over a period of several days or several months.

PCR, may be used and provides additional uses for oligonucleotides based upon the sequence encoding human Reg I γ . Such oligomers are generally chemically synthesized, but

they may be generated enzymatically or produced from a recombinant source. Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'-3') and one with antisense (3'-5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of
5 oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additionally, methods which may be used to quantitate the expression of a particular molecule include radiolabeling [Melby PC *et al.* (1993) J Immunol Methods 159:235-44] or biotinylating [Duplaa C *et al.* (1993) Anal Biochem 229-36] nucleotides, coamplification of a
10 control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition.
15 Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, and the like.

20 Therapeutic Use

Based upon its homology to mammalian reg/PSP proteins and its expression profile, the polynucleotide encoding human Reg I γ disclosed herein may be useful in the treatment of diabetes (*e.g.*, to induce regeneration of pancreatic β -cells). In addition, as the overexpression of other reg/PSP proteins has been shown to correlate with tumorigenesis and neurodegeneration,
25 inhibition of human Reg I γ expression may be therapeutic.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences (sense or antisense) to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense
30 of the sequence encoding human Reg I γ . See, for example, the techniques described in Sambrook *et al.* (*supra*) and Ausubel *et al.* (*supra*).

The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use the sequence encoding human Reg I γ as an investigative tool in sense [Yousoufian H and HF Lodish 1993 Mol Cell Biol 13:98-104] or antisense [Eguchi *et al.* (1991) Annu Rev Biochem 60:631-652] regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

Genes encoding human Reg I γ can be turned off by transfecting a cell or tissue with expression vectors which express high levels of a desired human Reg I γ fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the control regions of the sequence encoding human Reg I γ , *i.e.*, the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, *e.g.*, between -10 and +10 regions of the leader sequence, are preferred. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA were reviewed by Gee JE *et al.* [In: Huber BE and BI Carr (1994) *Molecular and Immunologic Approaches*, Futura Publishing Co, Mt Kisco NY].

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of the sequence encoding human Reg I γ .

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following

sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization
5 with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA
10 sequences encoding human Reg Iγ. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible
15 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified
20 forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Methods for introducing vectors into cells or tissues include those methods discussed *infra* and which are equally suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors are introduced into stem cells taken from the patient and clonally propagated for
25 autologous transplant back into that same patient is presented in US Patent Nos. 5,399,493 and 5,437,994, disclosed herein by reference. Delivery by transfection and by liposome are quite well known in the art.

Furthermore, the nucleotide sequences encoding human Reg Iγ disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new
30 techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

Detection And Mapping Of Related Polynucleotide Sequences

The nucleic acid sequence encoding human Reg I γ can also be used to generate hybridization probes for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price CM (1993; Blood Rev 7:127-34) and Trask BJ (1991; Trends Genet 7:149-54).

10 The technique of fluorescent *in situ* hybridization (FISH) of chromosome spreads has been described, among other places, in Verma *et al.* (1988) *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York NY. Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 15 1994 Genome Issue of Science (265:1981f). Correlation between the location of a the sequence encoding human Reg I γ on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

20 *In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. A recent example of an STS based map of the human genome was recently published by the Whitehead-MIT Center for Genomic Research [Hudson TJ *et al.* (1995) Science 270:1945-1954]. Often the placement of a gene on the chromosome of another mammalian 25 species such as mouse (Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28, 1995) may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery 30 techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 [Gatti *et al.* (1988) Nature 336:577-580], any sequences mapping to that area may represent associated

or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier or affected individuals.

Pharmaceutical Compositions

- 5 The present invention relates to pharmaceutical compositions which may comprise nucleotides, proteins, antibodies, agonists, antagonists, or inhibitors, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in
- 10 combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

Administration Of Pharmaceutical Compositions

Administration of pharmaceutical compositions is accomplished orally or parenterally.

- 15 Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into
- 20 preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA).

- Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral
- 25 administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient.

- Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the
- 30 mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as

methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

5 Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

10 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty
15 oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection
20 suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable
25 stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Manufacture And Storage

30 The pharmaceutical compositions of the present invention may be manufactured in a manner that known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the invention formulated in a acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of human Reg I γ , such labeling would include amount, frequency and method of administration.

Therapeutically Effective Dose

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, *e.g.*, tumor size and location; age, weight and gender of the patient; 5 diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of 10 about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature. See US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

15 It is contemplated, for example, that human Reg I γ can be used as a therapeutic molecule to induce cell growth (*e.g.*, to induce regeneration of pancreatic β -cells). It is further contemplated that antisense molecules capable of reducing the expression of human Reg I γ can be as therapeutic molecules to treat tumors associated with the aberrant expression of human Reg I γ . Still further it is contemplated that antibodies directed against human Reg I γ and capable of 20 neutralizing the biological activity of human Reg I γ may be used as therapeutic molecules to treat tumors associated with the aberrant expression of human Reg I γ .

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

25 I. COLNFET02 cDNA Library Construction

The COLNFET02 cDNA library was constructed from colon tissue obtained from a 20-week-old Caucasian female fetus. The pregnant mother was treated with erythromycin for seven days in the first trimester for bronchitis (specimen #RU95-10-0739; IIAM, Exton, PA).

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron 30 PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient

temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and DNase treated at 37°C. The RNA extraction was repeated with acid phenol pH 4.7 and precipitated with sodium acetate and ethanol as before. The mRNA was then isolated using the Qiagen Oligotex kit
5 (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013, Gibco/BRL). The commercial plasmid pSPORT 1 (Gibco/BRL) was digested with *EcoRI* restriction enzyme (New England Biolabs, Beverly, MA). The overhanging ends of the plasmid were filled in using
10 Klenow enzyme (New England Biolabs) and 2'-deoxynucleotide 5' triphosphates (dNTPs). The plasmid was self-ligated and transformed into the bacterial host, *E. coli* strain JM 109. An intermediate plasmid produced by the bacteria failed to digest with *EcoRI* confirming the desired loss of the *EcoRI* restriction site.

This intermediate plasmid (pSPORT 1-ΔRI) was then digested with *HindIII* restriction
15 enzyme (New England Biolabs) and the overhang was filled in with Klenow and dNTPs. A 10-mer linker of sequence 5'...CGGAATTC...3' was phosphorylated and ligated onto the blunt ends. The product of the ligation reaction was digested with *EcoRI* and self-ligated. Following transformation into JM109 host cells, plasmids were isolated and screened for the digestibility with *EcoRI* but not with *HindIII*. A single colony which met this criteria was designated pNICY
20 1. The plasmid produced by this colony was sequenced and found to contain several copies of the 10-mer linker. These extra linkers did not present a problem as they were eliminated when the vector was prepared for cloning.

The plasmid was tested for its ability to incorporate cDNAs from a library prepared using *NotI* and *EcoRI* restriction enzymes. Several clones were sequenced and a single clone
25 containing an insert of approximately 0.8 kb was selected to prepare a large quantity of the plasmid for library production. After digestion with *NotI* and *EcoRI*, the plasmid and the cDNA insert were isolated on an agarose gel and the vector was purified on a QIAQuick (Qiagen, Inc., Chatsworth, CA) column for use in library construction.

cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01, Pharmacia),
30 and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5α™ competent cells (Cat. #18258-012, Gibco/BRL).

II. Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit for Rapid Extraction Alkaline Lysis Plasmid Minipreps (Catalog #26173, QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, LIFE TECHNOLOGIES™) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4°C.

The cDNAs were sequenced by the method of Sanger *et al.* (1975, J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

Most of the sequences disclosed herein were sequenced according to standard ABI protocols, using ABI kits (Cat. Nos. 79345, 79339, 79340, 79357, 79355). The solution volumes were used at 0.25x - 1.0x concentrations. Some of the sequences disclosed herein were sequenced using different solutions and dyes which, unless otherwise noted, came from Amersham Life Science (Cleveland, OH).

First, stock solutions were prepared with HPLC water. The following solutions were each mixed by vortexing for 2 min: 1) Tris-EDTA (TE) Buffer was prepared by adding 49 ml water to 1 ml 50x Tris-EDTA concentrate, and 2) 10% Reaction Buffer was prepared by adding 45 ml water to 5 ml Concentrated Thermo Sequenase (TS) Reaction Buffer.

Second, 0.2 µM energy transfer (ET) primers were prepared in the following manner. Each primer tube was centrifuged prior to opening to assure that all primer powder was on the bottom of the tube. After each solubilization step, the mixture was vortexed for 2 min and then centrifuged for about 10 sec in a table-top centrifuge. 1 ml of 1x TE was added to each primer powder; adenine and cytosine dissolved primers (5-carboxyrhodamine-6G (R6G) and 6-carboxyfluorescein (FAM), respectively), were diluted with 9 ml 1x TE. Guanine and thymine dyes (N,N,N',N'-tetramethyl 6-carboxyrhodamine (TAM) and 6-carboxy-X-rhodamine (ROX), respectively) were diluted with 19 ml 1x TE.

Next, the sequencing reaction ready mix was prepared as follows: 1) nucleotides A and C (8 ml of each) were added to 6 ml ET primer and 18 ml TS reaction buffer; and 2) nucleotides G and T (8 ml of each) were added to 6 ml ET primer and 18 ml TS reaction buffer.

After vortexing for 2 min and centrifuging for 20 sec, the resulting solution was divided into tubes in volumes of 8 ml per tube in order to make 1x (A,C) and 2x (G,T) solutions.

Prior to thermal cycling, each nucleotide was individually mixed with DNA template in the following proportions:

Reagent	A(μ L)	C(μ L)	G(μ L)	T(μ L)
Reaction Ready Premix	2	2	4	4
DNA Template	1	1	2	2
Total Volume	3	3	6	6

These solutions underwent the following thermal cycling:

1. Rapid thermal ramp to 94°C (94°C for 20 sec)*
2. Rapid thermal ramp to 50°C (50°C for 40 sec)*
3. Rapid thermal ramp to 68°C (68°C for 60 sec)*
- * Steps 1, 2, and 3 were repeated for 15 cycles
4. Rapid thermal ramp to 94°C (94°C for 20 sec)**
5. Rapid thermal ramp to 68°C (68°C for 60 sec)**
- ** Steps 4 and 5 were repeated for 15 cycles
6. Rapid thermal ramp to 4°C and hold until ready to combine.

After thermal cycling, the A, C, G, and T reactions with each DNA template were combined. Then, 50 μ L 100% ethanol was added and the solution was spun at 4°C for 30 min. The supernatant was decanted and the pellet was rinsed with 100 μ L 70% ethanol. After being spun for 15 min, the supernatant was discarded and the pellet was dried for 15 min under vacuum. The DNA sample was dissolved in 3 μ L of formaldehyde/50 mM EDTA. The resulting samples were loaded on wells in volumes of 2 μ L per well for sequencing in ABI sequencers.

III. Homology Searching of cDNA Clones and Their Deduced Proteins

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT- 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence

comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF *et al.* (1990) J Mol Biol 215:403-10), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

A comparison of the full-length and partial cDNA sequences and the deduced amino acid sequences corresponding to the human *reg Iy* gene and Reg Iy protein with known nucleotide and protein sequences in GenBank revealed that the full-length human Reg Iy cDNA and protein sequences (*i.e.*, SEQ ID NOs:1 and 2) were unique (*i.e.*, not previously identified). Thus, SEQ

ID NO:1 represents the first identified human Reg I γ homolog. This search revealed that the human Reg I γ protein shared some homology with the human Reg I β and rat reg/lithostathine proteins (see alignment in Figure 2); more limited homology with nucleotide sequences encoding the human Reg I β and rat reg/lithostathine proteins was found.

5 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook *et al.*, *supra*).

Analogous computer techniques using BLAST (Altschul SF 1993 and 1990, *supra*) are
10 used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte, Palo Alto CA) (this technique is termed an "electronic northern"). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

15 The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

and it takes into account both the degree of similarity between two sequences and the length of
20 the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript
25 encoding human galectin-8 occurs. Abundance and percentage abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

Electronic northern analysis (Figure 3) revealed that mRNA encoding human Reg I γ
30 (SEQ ID NO:1) was present in libraries generated from the following tissues: ovary (Incyte library: OVARNOT03); ovarian tumor (Incyte library: OVARTUT01); colon (Incyte library: COLNNOT05); pancreas (Incyte library: PANCNOT08); and fetal colon (Incyte library: COLNFET02). This analysis revealed that human Reg I γ transcripts were most abundant in

adult ovary the tissues examined. In addition, this analysis revealed that human Reg Iy transcripts were expressed in tumor tissue (ovarian tumor). The Northern analysis showed that human Reg Iy transcripts were expressed in the pancreas, a feature in common with other members of the reg/PSP multigene family.

5 V. Extension Of The Sequence Encoding Human Reg Iy

The nucleic acid sequence of SEQ ID NO:2 is used to design oligo-nucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' sequence from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers allow the extension of the know sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest (US Patent Application 08/487,112, filed June 7, 1995, specifically incorporated by reference). The initial primers are designed from the cDNA using OLIGO® 4.06 Primer Analysis Software (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

- | | | |
|----|---------|--|
| 25 | Step 1 | 94°C for 1 min (initial denaturation) |
| | Step 2 | 65°C for 1 min |
| | Step 3 | 68°C for 6 min |
| | Step 4 | 94°C for 15 sec |
| | Step 5 | 65°C for 1 min |
| 30 | Step 6 | 68°C for 7 min |
| | Step 7 | Repeat step 4-6 for 15 additional cycles |
| | Step 8 | 94°C for 15 sec |
| | Step 9 | 65°C for 1 min |
| | Step 10 | 68°C for 7:15 min |
| 35 | Step 11 | Repeat step 8-10 for 12 cycles |
| | Step 12 | 72°C for 8 min |

Step 13 4°C (and holding)

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products are selected and cut out of the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc). After recovery of the DNA, Klenow enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16°C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook J *et al.*, *supra*). After incubation for one hour at 37°C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook J *et al.*, *supra*) containing 2xCarb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

- | | |
|--------|--|
| Step 1 | 94°C for 60 sec |
| Step 2 | 94°C for 20 sec |
| Step 3 | 55°C for 30 sec |
| Step 4 | 72°C for 90 sec |
| Step 5 | Repeat steps 2-4 for an additional 29 cycles |
| Step 6 | 72°C for 180 sec |
| Step 7 | 4°C (and holding) |

Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid and sequenced.

VI. Labeling And Use Of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs or mRNAs. Although the labeling of oligonucleotides, consisting of about 20

base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [γ - 32 P] adenosine triphosphate (Amersham, Chicago IL) and T4 polynucleotide kinase (DuPont NEN[®],
5 Boston MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 super fine resin column (Pharmacia). A portion containing 10^7 counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (*AseI*, *BglII*, *EcoRI*, *PstI*, *XbaI*, or *PvuII*; DuPont NEN[®]).

10 The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR[™] film (Kodak, Rochester NY) is exposed to the
15 blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually.

VII. Antisense Molecules

The sequence encoding human Reg I γ , or any part thereof, is used to inhibit *in vivo* or *in vitro* expression of the naturally occurring sequence. Although use of antisense oligonucleotides,
20 comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide complementary to the coding sequence of human Reg I γ as shown in Figures 1A and 1B is used to inhibit expression of the naturally occurring sequence. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A and 1B and used either to inhibit transcription by preventing
25 promoter binding to the upstream nontranslated sequence or translation of an human Reg I γ -encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the leader and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or early coding sequence of the polypeptide as shown in Figures 1A and 1B.

30 VIII. Expression Of Human Reg I γ

Expression of the human Reg I γ is accomplished by subcloning the cDNAs into appropriate vectors and transfecting the vectors into host cells. In this case, the cloning vector,

pSport1, previously used for the generation of the cDNA library is used to express human Reg I γ in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful
5 for transcription and a polylinker containing a number of unique restriction sites.

Induction of an isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first seven residues of β -galactosidase, about 5 to 15 residues of linker, and the full length human Reg I γ . The signal sequence provided by the vector directs the secretion of human Reg I γ into the bacterial growth media which can be used
10 directly in the following assay for activity. As the Reg I γ gene contains sequences encoding a signal sequence, these gene sequences may be deleted from the Reg I γ gene when the expression vector employed contains sequences encoding a signal sequence (alternatively, an expression vector which does not provide a signal sequence may be employed in conjunction with the full-length Reg I γ gene).

15 In addition, the human Reg I γ protein may be expressed as a fusion protein containing a histidine tag or GST tag using commercially available expression vectors [e.g., QIAExpress vectors (Qiagen) and pGex vectors (Pharmacia), respectively]. Suitable host cells and conditions for the induction/expression of the desired expression vectors are known to the art and available commercially. Histidine tagged human Reg I γ may be purified from *E. coli* extracts using metal
20 chelation chromatography using commercially available resins [e.g., Ni-NTA Agarose (Qiagen)]. GST-tagged human Reg I γ may be purified from *E. coli* extracts using affinity chromatography using commercially available resins [e.g., glutathione-Sepharose beads (Pharmacia)]. Several other expression systems are available and may be employed to express fusion proteins comprising human Reg I γ (e.g., pMAL vectors from New England Biolabs, Beverly, MA).

25 IX. Assay For Human Reg I γ Activity

The ability of human Reg I γ to induce cell growth can be demonstrated using pancreatic islets isolated from rat pancreas. Freshly isolated islets are prepared as described by Unno *et al.* [(1992) in *Pancreatic Islet Cell Regeneration and Growth*, Vinik, ed., Plenum Press, NY, pp. 61-69] and are exposed in *in vitro* culture to recombinant human Reg I γ prepared as described
30 above. The growth-promoting activity of human Reg I γ can be demonstrated using methods well known to the art, including staining of untreated and treated islet samples to observe differences in cell division index. A higher cell cycle index indicates human Reg I γ has induced cell growth.

Alternatively, the treated and untreated islet samples may be cultured in the presence of radiolabeled thymidine to examine *de novo* DNA synthesis as described [Francis *et al.* (1992), *supra*]. An increase rate of DNA synthesis in the treated islets as compared to the untreated islets indicates human Reg I γ has induced cell growth.

5 An extension of these assays can be used to compare the cell division indices of biopsied cell samples and observing the difference in cell division index. A higher cell cycle index indicates that human Reg I γ has increased cell growth in the treated tissue. Alternatively, these assays may be employed to observe the therapeutic effect of administration of inhibitors of human Reg I γ ; inhibitors of human Reg I γ would lower the cell cycle index in treated tissues.

10 Human Reg I γ contains a number of amino acid residues which are conserved among the CRD of C-type lectins and therefore human Reg I γ may bind carbohydrates. The ability of recombinant human Reg I γ to bind carbohydrates may be demonstrated by examining the ability of human Reg I γ to bind to affinity columns comprising carbohydrates (*e.g.*, lactose, maltose, D-mannose, D-galactose, etc. which are available from Sigma Chemical Corp., St. Louis, MO) or
15 by using the assay described by Christa *et al.* (1994), *supra*.

C-type lectins, including members of the reg/PSP gene family, are known to agglutinate bacteria. The ability of human Reg I γ to agglutinate bacteria is demonstrated using the assay described by Iovanna *et al.* [(1991), *supra*]. Briefly, bacteria (*e.g.*, *E. coli* strains KH802 or JM101) are grown at 37°C to stationary phase in L-broth. The bacteria are then collected by
20 centrifugation and washed in PBS. The washed bacteria are resuspended in PBS containing 0.5 mM CaCl₂ (PBS/CaCl₂) and are placed in the wells of microtiter plates at a concentration of approximately 5 x 10⁷ bacteria/200 μ l PBS/CaCl₂. Human Reg I γ is then added at a variety of concentrations (*e.g.*, 1 to 50 μ g/ml) and the presence of macroscopic aggregation is monitored following a 3 hour incubation at 25°C. Concanavalin A and albumin at 50 μ g/ml may be
25 employed as positive and negative controls, respectively.

X. Production Of Human Reg I γ Specific Antibodies

Human Reg I γ substantially purified using polyacrylamide gel electrophoresis (PAGE) (Sambrook, *supra*) is used to immunize suitable animals (*e.g.*, rabbits, hamsters, rats, mice, goats, sheep, etc.) and to produce antibodies using standard protocols (alternatively, recombinant human
30 Reg I γ fusion proteins may be purified by affinity or metal chelation chromatography and used to immunize animals). The amino acid sequence translated from human Reg I γ is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity and a

corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Analysis to select appropriate epitopes, such as those near the C-terminus or in hydrophilic regions is described by Ausubel FM *et al.* (*supra*).

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM *et al.*, *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Purified human Reg I γ (native or fusion proteins) may be used to generate antibodies which react specifically with the human Reg I γ protein. The production of both polyclonal and monoclonal antibodies utilize techniques standard to the art. Polyclonal antibodies contain a mixture of different types of antibodies that are specific for many different antigens present on the immunogen. Monoclonal antibodies contain a single species of antibody having a defined specificity.

Briefly, polyclonal antibodies are generated by immunization of a host animal with a purified protein. The serum of the immunized animal will contain antibodies directed against one or more epitopes of the injected protein. When rabbits are used for the production of polyclonal antibodies specific for human Reg I γ , 50 to 1000 μ g of purified human Reg I γ is mixed with complete Freund's adjuvant and administered subcutaneously (s.c.) to the rabbit. Typically, multiple s.c. injections, each containing a maximum volume of about 400 μ l are administered (up to 10 injections may be performed per animal). Alternatively, the immunogen may administered by intramuscular or intradermal injection. Four to six weeks following the initial or primary injection, secondary or booster injections are administered (these may utilize incomplete Freund's adjuvant). Additional boosts are given in 4-6 week intervals following the last injection. Immunized rabbits are bled (*e.g.*, using the marginal ear vein) and the serum is screened for the presence of antibodies which react specifically with human Reg I γ (*e.g.*, by ELISA screening).

Immunization of mice is conducted as described above with the exception that the dose of antigen is 10-50 μ g per injection (250 μ l antigen solution mixed with 250 μ l complete Freund's adjuvant) and injection is given intraperitoneally (i.p.). The first boost is given two weeks later and employs incomplete Freund's adjuvant; subsequent boosts are given at about 3 week

intervals. Serum is collected from the immunized mice (e.g., by tail bleeding) and is screened for the presence of antibodies which react specifically with human Reg I γ (e.g., by ELISA screening).

Monoclonal antibodies are produced by immunizing a host animal with purified human
5 Reg I γ protein (native or fusion). Once the host has produced antibodies specific for human Reg I γ protein, the spleen of the host is removed. The plasma cells present in the spleen of the immune host are then fused with a myeloma cell (the "fusion partner") to produce hybridoma cells. When mice are immunized for the production of plasma cells to be used to generate hybridomas, suitable fusion partners include the X63Ag8.653, Sp2/0-Ag14, FO, NSI/1-Ag4-1,
10 NSO/1 and FOX-NY cell lines [*Antibodies: A Laboratory Manual*, Harlow and Lane, Eds. (1988) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p. 144]. When rats are immunized for the production of plasma cells to be used to generate hybridomas, suitable fusion partners include the YB2/0 and IR983F cell lines (Harlow and Lane, *supra*). Mice or rats are immunized as described above. Following the generation of specific anti-human Reg I γ
15 antibodies in the animals (typically following 2 to 3 booster injection and about 56 days following the initial injection), spleens are removed and splenocytes are fused (e.g., using polyethylene glycol) with the desired fusion partner. The fused cells are diluted in the appropriate selective medium and plated in multiwell culture plates. Each hybridoma cell produces a single type of antibody. Culture supernatant from individual hybridoma cells
20 (removed from the hybridomas about 1 week following plating) is screened using standard techniques to identify those hybridoma cells expressing monoclonal antibodies reactive with human Reg I γ (*see* Harlow and Lane, *supra* for a review of screening techniques).

When a fusion protein is utilized for the production of antibodies, the resulting antibodies may contain antibodies directed against the fusion partner (e.g., GST). These anti-fusion partner
25 antibodies may be removed from a polyclonal sera by chromatography of the sera on a column containing the fusion partner immobilized to a solid support such as Sepharose beads (Pharmacia). For example, to remove anti-GST antibodies from a polyclonal sera raised against a GST fusion protein, the sera is chromatographed on a resin comprising the GST protein covalently linked to glutathione Sepharose. Anti-fusion partner antibodies may be excluded
30 during the routine screening of hybridomas during the production of monoclonal antibodies.

XI. Purification Of Naturally Occurring Human Reg I γ Using Specific Antibodies

Naturally occurring or recombinant human Reg I γ is substantially purified by immunoaffinity chromatography using antibodies specific for human Reg I γ . An immunoaffinity column is constructed by covalently coupling human Reg I γ antibody to an activated chromatographic resin such as CnBr-activated Sepharose (Pharmacia Biotech). After the
5 coupling, the resin is blocked and washed according to the manufacturer's instructions.

Extracts from cells expressing human Reg I γ are prepared by methods well known in the art (*e.g.*, disruption of fresh or frozen ovarian or pancreatic tissue followed by centrifugation to remove cellular debris). Alternatively, a recombinant human Reg I γ fragment containing an appropriate signal sequence (the native Reg I γ or a heterologous signal sequence may be
10 employed) may be secreted in useful quantity into the medium in which transfected cells are grown.

A human Reg I γ -containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of human Reg I γ (*e.g.*, high ionic strength buffers in the presence of detergent). The column is eluted under
15 conditions that disrupt antibody/human Reg I γ binding (*e.g.*, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and human Reg I γ is collected.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit
20 of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: INCYTE PHARMACEUTICALS, INC.
- (ii) TITLE OF THE INVENTION: NOVEL HUMAN REG PROTEIN
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: US
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) PCT APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Filed Herewith
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/729,103
 - (B) FILING DATE: 08-OCT-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0138 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 650-855-0555
 - (B) TELEFAX: 650-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 158 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: COLNFET02
 - (B) CLONE: 1310334

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Ala Ser Arg Ser Met Arg Leu Leu Leu Leu Leu Ser Cys Leu Ala
 1          5          10          15
Lys Thr Gly Val Leu Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro
          20          25          30
Gly Trp Phe Tyr His Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu
          35          40          45
Arg Asn Trp Ser Asp Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly
          50          55          60
Ala His Leu Ala Ser Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala
          65          70          75          80
Glu Tyr Ile Ser Gly Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu
          85          90          95
His Asp Pro Gln Lys Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met
          100          105          110
Tyr Leu Tyr Arg Ser Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His
          115          120          125
Cys Ala Glu Met Ser Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn
          130          135          140
Glu Cys Asn Lys Arg Gln His Phe Leu Cys Lys Tyr Arg Pro
          145          150          155

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 614 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: COLNFET02
- (B) CLONE: 1310334

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

TGAAGAAGGC AGGGGCCCTT AGAGTCTTGG TTGCCAAACA GATTTCAGAG TCAAGGAGAA      60
CCCAGGAGTT TCAAAGAAGC GCTAGTAAGG TCTCTGAGAT CCTTGCACTA GCTACATCCT      120
CAGGGTAGGA GGAAGATGGC TTCCAGAAGC ATGCGGCTGC TCCTATTGCT GAGCTGCCTG      180
GCCAAACAG GAGTCCTGGG TGATATCATC ATGAGACCCA GCTGTGCTCC TGGATGGTTT      240
TACCACAAGT CCAATTGCTA TGTTACTTTC AGGAAGCTGA GGAAGTGGTC TGATGCCGAG      300
CTCGAGTGTC AGTCTTACGG AACCGGAGCC CACCTGGCAT CTATCCTGAG TTAAAGGAA      360
GCCAGCACCA TAGCAGAGTA CATAAGTGGC TATCAGAGAA GCCAGCCGAT ATGGATTGGC      420
CTGCACGACC CACAGAAGAG GCAGCAGTGG CAGTGGATTG ATGGGGCCAT GTATCTGTAC      480
AGATCCTGGT CTGGCAAGTC CATGGGTGGG AACAAAGCACT GTGCTGAGAT GAGCTCCAAT      540
AACAACTTTT TAAC TTGGAG CAGCAACGAA TGCAACAAGC GCCAACACTT CCTGTGCAAG      600
TACCGACCAT AGAG                                     614

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 165 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 393209

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Thr Arg Asn Lys Tyr Phe Ile Leu Leu Ser Cys Leu Met Val Leu
 1      5      10      15
Ser Pro Ser Gln Gly Gln Glu Ala Glu Glu Asp Leu Pro Ser Ala Arg
 20      25      30
Ile Thr Cys Pro Glu Gly Ser Asn Ala Tyr Ser Ser Tyr Cys Tyr Tyr
 35      40      45
Phe Met Glu Asp His Leu Ser Trp Ala Glu Ala Asp Leu Phe Cys Gln
 50      55      60
Asn Met Asn Ser Gly Tyr Leu Val Ser Val Leu Ser Gln Ala Glu Gly
 65      70      75      80
Asn Phe Leu Ala Ser Leu Ile Lys Glu Ser Gly Thr Thr Ala Ala Asn
 85      90      95
Val Trp Ile Gly Leu His Asp Pro Lys Asn Asn Arg Arg Trp His Trp
100      105      110
Ser Ser Gly Ser Leu Phe Leu Tyr Lys Ser Trp Asp Thr Gly Tyr Pro
115      120      125
Asn Asn Ser Asn Arg Gly Tyr Cys Val Ser Val Thr Ser Asn Ser Gly
130      135      140
Tyr Lys Lys Trp Arg Asp Asn Ser Cys Asp Ala Gln Leu Ser Phe Val
145      150      155      160
Cys Lys Phe Lys Ala
165

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 474306

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ala Gln Thr Asn Ser Phe Phe Met Leu Ile Ser Ser Leu Met Phe
 1      5      10      15
Leu Ser Leu Ser Gln Gly Gln Glu Ser Gln Thr Glu Leu Pro Asn Pro
 20      25      30
Arg Ile Ser Cys Pro Glu Gly Thr Asn Ala Tyr Arg Ser Tyr Cys Tyr
 35      40      45
Tyr Phe Asn Glu Asp Pro Glu Thr Trp Val Asp Ala Asp Leu Tyr Cys
 50      55      60
Gln Asn Met Asn Ser Gly Asn Leu Val Ser Val Leu Thr Gln Ala Glu
 65      70      75      80
Gly Ala Phe Val Ala Ser Leu Ile Lys Glu Ser Ser Thr Asp Asp Ser
 85      90      95
Asn Val Trp Ile Gly Leu His Asp Pro Lys Lys Asn Arg Arg Trp His
100      105      110
Trp Ser Ser Gly Ser Leu Val Ser Tyr Lys Ser Trp Asp Thr Gly Ser
115      120      125

```


WO 98/16640

PCT/US97/18174

Pro	Ser	Ser	Ala	Asn	Ala	Gly	Tyr	Cys	Ala	Ser	Leu	Thr	Ser	Cys	Ser
	130					135					140				
Gly	Phe	Lys	Lys	Trp	Lys	Asp	Glu	Ser	Cys	Glu	Lys	Lys	Phe	Ser	Phe
145					150					155					160
Val	Cys	Lys	Phe	Lys	Asn										
				165											

CLAIMS

1. A substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1.
2. The polypeptide of Claim 1, wherein said purified polypeptide comprises a portion of
5 said SEQ ID NO:1 having a length greater than 10 amino acid residues.
3. An isolated polynucleotide sequence encoding the polypeptide of Claim 1.
4. The polynucleotide sequence of Claim 3 comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof.
5. The polynucleotide sequence of Claim 4, wherein said portion of said polynucleotide
10 comprises fragments of SEQ ID NO:2 having a length greater than 30 nucleotides.
6. The polynucleotide sequence of Claim 4 comprising the complement of the nucleic acid sequence of SEQ ID NO:2 or variants thereof.
7. A polynucleotide sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO:2.
- 15 8. A method for detecting the presence of polynucleotide sequences encoding at least a portion of human Reg Iy in a biological sample, comprising the steps of:
 - a) providing:
 - i) a biological sample suspected of containing nucleic acid corresponding
to the polynucleotide sequence of SEQ ID NO:2;
 - 20 ii) the polynucleotide of SEQ ID NO:2, or a fragment thereof;
 - b) combining said biological sample with said polynucleotide under conditions such that a hybridization complex is formed between said nucleic acid and said polynucleotide,
and
 - c) detecting said hybridization complex.
- 25 9. The method of Claim 8, wherein, said nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2 is ribonucleic acid.
10. The method of Claim 9, wherein said detected hybridization complex correlates with expression of the polynucleotide of SEQ ID NO:2 in said biological sample.
11. The method of Claim 8, wherein, said nucleic acid corresponding to the
30 polynucleotide sequence of SEQ ID NO:2 is deoxyribonucleic acid.

12. The method of Claim 11, wherein said detecting of said hybridization complex comprises conditions that permit the detection of alterations in the polynucleotide of SEQ ID NO:2 in said biological sample.

13. An antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2.

14. A pharmaceutical composition comprising the antisense molecule of Claim 13 and a pharmaceutically acceptable excipient.

15. The polynucleotide sequence of Claim 4, wherein said polynucleotide sequence is contained on a recombinant expression vector.

16. The polynucleotide sequence of Claim 15, wherein said expression vector containing said polynucleotide sequence is contained within a host cell.

17. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, the method comprising the steps of:

a) culturing the host cell of Claim 16 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

18. A pharmaceutical composition comprising a substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

19. A purified antibody which binds specifically to the polypeptide of Claim 1.

20. A pharmaceutical composition comprising the antibody of Claim 19 and a pharmaceutically acceptable excipient.

21. A method for detecting the expression of human Reg I γ in a biological sample comprising the steps of:

a) providing:

- i) a biological sample suspected of expressing human Reg I γ protein; and
- ii) the antibody of Claim 19;

b) combining said biological sample and said antibody under conditions such that an antibody:protein complex is formed; and

c) detecting said complex wherein the presence of said complex correlates with the expression of said protein in said biological sample.

5' TGA AGA AGG CAG GGG CCC TTA GAG TCT TGG TTG CCA AAC AGA TTT GCA GAT CAA 54
 63 GGA GAA CCC AGG AGT TTC AAA GAA GCG CTA GTA AGG TCT CTG AGA TCC TTG CAC 108
 117 TAG CTA CAT CCT CAG GGT AGG AGG AAG ATG GCT TCC AGA AGC ATG CCG CTG CTC 162
 126 M A S R S M R L L
 135 144 153 162
 171 CTA TTG CTG AGC TGC CTG GCC AAA ACA GGA GTC CTG GGT GAT ATC ATC ATG AGA 216
 180 L L L S C L A A K T G V L G D I I M R
 189 198 207
 225 CCC AGC TGT GCT CCT GGA TGG TTT TAC CAC AAG TCC AAT TGC TAT GGT TAC TTC 270
 234 P S C A P G W F Y H K S N C Y G Y F
 243 252 261
 279 AGG AAG CTG AGG AAC TGG TCT GAT GCC GAG CTC GAG TGT CAG TCT TAC GGA AAC 324
 288 R K L R N W S D A E L E C Q S Y G N
 297 306 315 324
 333 GGA GCC CAC CTG GCA TCT ATC CTG AGT TTA AAG GAA GCC AGC ACC ATA GCA GAG 378
 342 G A H L A S I L S L K E A S T I A E
 351 360 369 378

FIGURE 1A

2/7

387	TAC ATA	396	GGC TAT	405	AGA AGC	414	CCG ATA	423	GGC ATT	432	CAC GAC	CCA
Y I S	G Y Q	R S Q	P I W	I G L	H D P							
441	AGG CAG	450	TGG CAG	459	ATT GAT	468	GGG GCC	477	TAT CTG	486	TAC AGA	TCC
Q K R	Q Q W	Q W Q	I D G	A M Y	L Y R	S						
495	GGC AAG	504	TCC ATG	513	GGG AAC	522	TGT GCT	531	GAG ATG	540	AGC TCC	AAT
W S G	K S M	G G G	N K H	C A E	M S S	N						
549	TTT TTA	558	TGG AGC	567	AAC AAC	576	TGC AAC	585	CGC CAA	594	CAC TTC	CTG
N N F	L T W	S S S	E C N	K R Q	H F L							
603	TAC CGA	612	TAG AG	3'								
C K Y	R P *											

FIGURE 1B

1	M	A	S	R	S	M	R	L	L	L	S	C	L	-	-	-	-	A	K	T	G	V	L	G	D	I	I	M	-	-	R	P	S	C	A	P	G	1310334				
1	M	A	-	Q	T	N	S	F	F	M	L	I	S	S	L	M	F	L	S	L	S	Q	G	Q	E	S	Q	T	E	L	P	N	P	R	I	S	C	P	E	G	GI 474306	
1	M	T	-	R	-	N	K	Y	F	I	L	S	C	L	M	V	L	S	P	S	Q	G	Q	E	A	E	E	D	L	P	S	A	R	I	T	C	P	E	G	GI 393209		
34	W	F	Y	H	K	S	N	C	Y	G	Y	F	R	K	L	R	N	W	S	D	A	E	L	E	C	Q	S	Y	G	N	G	A	H	L	A	S	I	L	S	L	1310334	
40	T	N	A	Y	R	S	Y	C	Y	F	N	E	D	P	E	T	W	V	D	A	D	L	Y	C	Q	N	M	N	S	G	-	N	L	V	S	V	L	T	Q	GI 474306		
39	S	N	A	Y	S	S	Y	C	Y	F	M	E	D	H	L	S	W	A	E	A	D	L	F	C	Q	N	M	N	S	G	-	Y	L	V	S	V	L	S	Q	GI 393209		
74	K	E	A	S	T	I	A	E	Y	I	S	G	Y	Q	R	S	Q	P	-	I	W	I	G	L	H	D	P	Q	K	R	Q	Q	W	I	D	G	A	M	1310334			
79	A	E	G	A	F	V	A	S	L	I	K	E	S	S	T	D	D	S	N	V	W	I	G	L	H	D	P	K	K	N	R	R	W	H	W	S	S	G	S	L	GI 474306	
78	A	E	G	N	F	L	A	S	L	I	K	E	S	G	T	T	A	A	N	V	W	I	G	L	H	D	P	K	N	N	R	R	W	H	W	S	S	G	S	L	GI 393209	
113	Y	L	Y	R	S	W	S	G	K	S	M	G	G	N	K	H	-	-	C	A	E	M	S	S	N	N	N	F	L	T	W	S	S	N	E	C	N	K	R	Q	1310334	
119	V	S	Y	K	S	W	D	T	G	S	P	S	S	A	N	A	G	Y	C	A	S	L	T	S	C	S	G	F	K	K	W	K	D	E	S	C	E	K	K	F	GI 474306	
118	F	L	Y	K	S	W	D	T	G	Y	P	E	N	N	S	N	R	G	Y	C	V	S	V	T	S	N	S	G	Y	K	K	W	R	D	N	S	C	D	A	Q	L	GI 393209
151	H	F	L	C	K	Y	R	P	1310334																																	
159	S	F	V	C	K	F	K	N	GI 474306																																	
158	S	F	V	C	K	F	K	A	GI 393209																																	

FIGURE 2

4/7

Library	Lib Description	Abun	Pct Abun
<u>QVARNOT03</u>	ovary, 43 F, match to OVARTUT01	<u>5</u>	0.1932
<u>OVARTUT01</u>	ovarian tumor, 43 F, match to OVARNOT03	<u>3</u>	0.0968
<u>COLNNOT05</u>	colon, 40 M, match to PANCCTUT01	<u>2</u>	0.0577
<u>PANCNOT08</u>	pancreas, 65 F, match to PANCCTUT01	<u>1</u>	0.0254
<u>COLNFEET02</u>	colon, fetal F	<u>1</u>	0.0142

FIGURE 3

5/7




FIGURE 4

6/7




FIGURE 5

	10	20	30	40	50	60	70
	MASRSMRLLLLSCLAKTGVLDIIMRPSCAPGWFYHKSNCYGYFRKLRNWSDAELECQSYGNGAHLASI						
HELIX	hhhhhhhhhh				HHHHHHHHHh		hHHhh
SHEET	sSSSSSSSSSSSSSSSSSS		SSS	sSSS	sSSS	sss	SSSS
TURN	TTTTT	TTTTTTTTT		TTTTTTTTT	TTTT	TTTTTTTTT	
COIL	C						
	80	90	100	110	120	130	140
	LSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQOWIDGAMLYRSWSGKSMGKNKCAEMSSNNNNFLT						
HELIX	hhHHHHHHhh	hhhhhh	hhHHHHHHHHH	hhHHh			
SHEET	Sss	SSSSs	SSSSSS	ssssssssssssSSSSSS	SSS		SSS
TURN	TTTTTTTTT	TTTT	TTTTTTTTTTTTT		TTTTTTTTTTTTT	TTTTTTTTT	
COIL							
	150						
	WSSNECNKRQHF LCKYRP						
HELIX	hhhhhh						
SHEET	s	SSSSSS					
TURN	TTTTTTTTT						
COIL		CC					

FIGURE 6

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 97/18174

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 A61K38/17 C12N15/11 A61K31/70
C12N1/21 C12N15/62 C07K19/00 C12Q1/68 G01N33/50
G01N33/60 C07K16/28 G01N33/53 A61K39/395 //(C12N1/21,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 96 39541 A (HUMAN GENOME SCIENCES INC ;SOPPET DANIEL R (US); LI YI (US); DILLO) 12 December 1996 see page 3, paragraph 4 - page 21, paragraph 2 see page 28, paragraph 3 - page 39, paragraph 4 see page 51 - page 57; claims --- -/--	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

13/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18174

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAKUO WATANABE ET AL.: "Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The REG protein, Pancreatic Stone Protein, and Pancreatic Thread Protein are one and the same product of the gene" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 13, 5 May 1990, pages 7432-7439, XP000126179 cited in the application ---	
A	UNNO M. ET AL.: "Structure, chromosomal localization, and expression of mouse reg genes, reg I and reg II" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 21, 25 July 1993, pages 15974-15982, XP002053455 cited in the application ---	
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18174

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Database EMBL, entry HSZZ19915, Accession number AA314779. 18.Apr11.1997. XP002053456 see the whole document -----	1-7

information on patent family members

PCT/US 97/18174

Form PCT/ISA/210 (patent family annex) (July 1992)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, A61K 38/17, C12N 15/11, A61K 31/70, C12N 1/21, 15/62, C07K 19/00, C12Q 1/68, G01N 33/50, 33/60, C07K 16/28, G01N 33/53, A61K 39/395 // (C12N 1/21, C12R 1:19)</p>	A1	<p>(11) International Publication Number: WO 98/16640</p> <p>(43) International Publication Date: 23 April 1998 (23.04.98)</p>
<p>(21) International Application Number: PCT/US97/18174</p> <p>(22) International Filing Date: 7 October 1997 (07.10.97)</p> <p>(30) Priority Data: 08/729,103 11 October 1996 (11.10.96) US</p> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). GOLLI, Surya, K. [IN/US]; 620 Iris Avenue #338, Sunnyvale, CA 94086 (US).</p> <p>(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p>		<p>(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>

(54) Title: HUMAN REG I-GAMMA PROTEIN

```

1  M A S R S M R L L L L L S C L - - - A K T G V L G D I I M - - - R P S C A P G 1310334
1  M A - Q T N S F F M L I S S L M F L S L S Q G Q E S Q T E L F N P R I S C P E G GI 474306
1  M T - E - N K Y F I L L S C L M V L S P S O G Q E A E E D L P S A R I T C P E G GI 393209

34 W F Y H K S N C Y G Y F R K L R N W S D A E L E C Q S Y G N G A H L A S I L S L 1310334
40 T N A Y R S Y C Y Y F N E D P E T W V D A D L Y C Q N M N S G - N L V S V L T Q GI 474306
39 S N A Y S S Y C Y Y F M E D H L S W A E A D L F C Q N M N S G - Y L V S V L S Q GI 393209

74 K E A S T I A E Y I S G Y Q R S Q P - I W I G L H D P Q K R Q Q W Q W I D G A M 1310334
79 A E G A F V A S L I K E S S T D D S N V W I G L H D P K K N R R W H W S S G S L GI 474306
78 A E G N F L A S L I K E S G T T A A N V W I G L H D P K N N R R W H W S S G S L GI 393209

113 Y L Y R S W S G K S M G G N K H - - C A E M S S N N N F L T W S S N E C N K R Q 1310334
119 V S Y K S W D T G S P S A N A G Y C A S L T S C S G F K K W K D E S C E K K F GI 474306
118 F L Y K S W D T G Y P N N S N R G Y C V S V T S N S G Y K K W R D N S C D A Q L GI 393209

151 H F L C K Y R P 1310334
159 S F V C K F K N GI 474306
158 S F V C K F K A GI 393209

```

(57) Abstract

The present invention provides a polynucleotide (Reg I-gamma) which identifies and encodes a human Reg I-gamma. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human Reg I-gamma. The invention also provides for the use of purified Reg I-gamma and its agonists in the production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I-gamma. Additionally, the invention provides for the use of Reg I-gamma antagonists and inhibitors, including antisense molecules to Reg I-gamma in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I-gamma. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding Reg I-gamma and anti-human Reg I-gamma antibodies which specifically binds to Reg I-gamma.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HUMAN REG I-GAMMA PROTEIN

TECHNICAL FIELD

The present invention relates to nucleic acid and amino acid sequences of a novel human Reg protein, which comprises a soluble C-type lectin. This novel human Reg protein shares
5 features with other proteins in the reg/PSP multigene family which are involved in cell growth. The present invention relates to the use of these novel sequences in the diagnosis, prevention and treatment of disease.

BACKGROUND ART

Lectins are proteins which are defined by their ability to bind carbohydrates specifically
10 and to agglutinate cells. Lectins have been shown to be involved in a wide variety of cellular functions including cell-cell and cell-matrix interactions. Lectins are widespread among plants, invertebrates and mammals.

Animal lectins have been grouped into four distinct families: 1) C-type lectins, which include selectins; 2) P-type lectins; 3) galectins (formerly termed S-type lectins or S-Lac lectins);
15 and 4) pentraxins [Barondes SH *et al.* (1994) J. Biol. Chem. 269:20807-10]. The C-type lectins bind carbohydrate ligands in a Ca^{2+} -dependent manner and are structurally related to the asialoglycoprotein receptor. Selectins, a subcategory of the C-type lectins, are composite transmembrane molecules which are involved in cell-cell interactions. The selectins include lymphocyte homing receptors and platelet/endothelial cell surface receptors [Stoolman (1989)
20 Cell 56:907-10].

C-type animal lectins contain Ca^{2+} -dependent carbohydrate-recognition domains (CRDs). The prototypical C-type animal lectins are integral membrane proteins (*e.g.*, the asialoglycoprotein receptor); however, a number of soluble C-type animal lectins have been identified. One group of soluble C-type animal lectins, termed collectins or Group III C-type
25 lectins, comprise proteins having both lectin- (*i.e.*, CRD) and collagenous-like domains within a single polypeptide [Drickamer (1993) Curr. Opin. Struct. Biol. 3:393]. Another group of soluble C-type animal lectins, termed Group IV C-type lectins, comprise free CRDs which are not joined to other polypeptide domains (other than a signal peptide utilized in secretion) [Drickamer (1993), *supra*]. The soluble C-type animal lectins comprising free CRDs found in mammals are
30 most closely related to proteins identified in invertebrates and lower vertebrates (*e.g.*, snakes).

Proteins recognized as members of the Group IV C-type lectins appear to be members of a multigene family termed the reg/PSP multigene family [Drickamer (1993), *supra* and Unno *et*

al. (1993) *J. Biol. Chem.* 268:15974]. The reg/PSP multigene family comprises genes encoding secretory proteins which are expressed in the pancreas; the ectopic expression (*i.e.*, expression in a tissue which does not normally express reg/PSP proteins) of some members of the reg/PSP family is associated with disease states such as tumors and Alzheimer's disease.

5 The first member of the reg/PSP multigene family was identified in a cDNA library derived from rat regenerating pancreatic islets [Terazono *et al.* (1988) *J. Biol. Chem.* 263:2111]. This gene was termed reg (*regenerating* gene) and is now known as the regI α gene; homologs of the rat regI α gene have been identified in humans [Watanabe *et al.* (1990) *J. Biol. Chem.* 265:7432] and mice [Unno *et al.* (1993), *supra*]. The regI α gene encodes a 166 amino acid
10 protein including a 22 amino acid signal peptide which has been called by different investigators reg protein, regI α protein, lithostathine, islet cell regeneration factor (ICRF), pancreatic stone protein (PSP) and pancreatic thread protein (PTP) [Terazono *et al.* (1988), *supra*; Moriizumi *et al.* (1994) *Biochem. Biophys. Acta* 1217:199; Dusetti *et al.* (1993) *Biochem. Biophys. Acta* 1174:99; Rouquier *et al.* (1991) *J. Biol. Chem.* 266:786; and de la Monte *et al.* (1990) *J. Clin.*
15 *Invest.* 86:1004]. The mature form of the regI α /lithostathine protein lacks not only the signal peptide but an additional 11 amino-terminal amino acids which are removed by cleavage by trypsin in pancreatic juice [Giogri *et al.* (1989) *J. Clin. Invest.* 84:100 and Rouimi *et al.* (1987) *FEBS Lett.* 216:195].

RegI α mRNA is expressed in normal human tissues most abundantly in the pancreas with
20 moderate expression seen in the gastric mucosa and very low levels of expression in the kidney [Watanabe *et al.* (1990) *J. Biol. Chem.* 265:7432]. In the pancreas, regI α protein is expressed at high levels in normal exocrine pancreas cells. No or very low levels of expression are seen in normal islet cells; in contrast, expression of regI α /lithostathine protein is increased dramatically in regenerating islet cells as compared to normal islet cells [Francis *et al.* (1992) *Diabetologia*
25 35:238]. The clear association between *reg* gene expression and islet cell replication *in vitro* has lead to the suggestion that the regI α /lithostathine protein has a growth-promoting activity for islet β -cells [Unno *et al.* (1993), *supra*].

The regI α /lithostathine protein has been shown to control CaCO₃ crystal growth in pancreatic juice [Bernard *et al.* (1992) *Gastroenterol.* 99:900]. RegI α /lithostathine protein
30 accounts for up to 10% of total protein in pancreatic juice and is present in the pancreatic juice of a variety of mammals including humans, cows, pigs, dogs, rats, and monkeys [Bernard *et al.* (1991) *Pancreas* 6:162]. Pancreatic juice is normally supersaturated with bicarbonate and

calcium which leads to the formation of CaCO_3 crystals. RegI α /lithostathine controls the size of the crystals thereby preventing clogging of pancreatic ducts; a amino-terminal undecapeptide is released from the human reg/lithostathine protein by treatment with trypsin has been shown to contain the inhibitory activity of this protein on CaCO_3 crystal growth [Bernard *et al.* (1992)

5 Gastroenterol. 103:1277]. Patients with chronic calcifying pancreatitis exhibit a reduction in regI α gene expression [Giorgi *et al.* (1989) J. Clin. Invest. 84:100].

Human regI α mRNA is expressed in colon and rectal tumors although it is not expressed in normal colon or rectal tissue. Thus, ectopic expression of regI α protein is associated with tumorigenesis. Elevated levels of regI α protein has been found in the brains of patients suffering
10 from Alzheimer's disease as well as in the brains of middle-aged individuals with Down's syndrome [Ozturk *et al.* (1989) Proc. Natl. Acad. Sci. USA 86:419 and de la Monte *et al.* (1990) J. Clin. Invest. 86:1004]. RegI α mRNA is expressed in the developing human brain, but not in normal adult brain; expression of regI α is seen in adult brain which undergoing regenerative sprouting. Given its pattern of expression (*e.g.*, expression in regenerating pancreatic islets and
15 brain, expression in tumors), it appears that regI α protein is associated with cell growth.

A gene closely related to the regI α gene, called regI β , has been identified in humans [Morizumi *et al.* (1994) Biochem. Biophys. Acta 1217:199]. RegI β mRNA is appears to be expressed exclusively in the pancreas in contrast to regI α mRNA is expressed in stomach and kidney, as well as in pancreas. The regI β protein contains 166 amino acids and has a 22 amino
20 acid signal sequence. The regI α and regI β proteins are 87% identical in amino acid sequence; the regI α and regI β genes share 91% homology over their respective coding regions.

Other members of the reg/PSP multigene family are the genes encoding pancreatitis-associated proteins (PAPs) which have been identified in humans, mice and rats [Iovanna *et al.* (1991) J. Biol. Chem. 266:24664; Orelle *et al.* (1992) J. Clin. Invest. 90:2284; Itoh and Teraoka
25 (1993) Biochem. Biophys. Acta 1172:184; and Dusetti *et al.* (1994) Genomics 19:108]. The reg/lithostathine and PAP proteins characterized to date share about 45-65% identity on the amino acid level.

The PAP proteins are secretory proteins which are stored in zymogen granules prior to secretion [Keim *et al.* (1991) Gastroenterol. 100:775]; PAP is present at low levels in normal
30 pancreas but is rapidly overexpressed during the acute phase of pancreatitis. PAP, like other members of the reg/PSP family, shares sequence similarity with the carbohydrate-binding domain of C-type lectins which likely explains the ability of PAP to induce aggregation of bacteria

[Iovanna *et al.* (1991), *supra*]. The ability to aggregate bacteria has lead to the suggestion that PAP is involved in the control of bacterial proliferation, a frequent complication of pancreatitis. PAP has been shown to be able to bind lactose [Christa *et al.* (1994) FEBS Lett. 337:114].

Three PAP genes, PAP I-III, have been identified in rats. All three PAP genes are
5 expressed during the acute phase of pancreatitis. Rat PAP I and PAP III are expressed constitutively in the intestine and their expression is induced by feeding. Rat PAP II is not expressed in the intestine. Rat PAP I and PAP III share 66% amino acid identity; rat PAP II and PAP III share 63% amino acid identity; rat PAP I and PAP II share 58% amino acid identity. A homologue of rat PAP I has been identified in cows [BPTP; de la Monte *et al.* (1990), *supra*].

10 A human homolog of the rat PAP I gene, human PAP or human PAP I, has been identified [Orelle *et al.* (1992) J. Clin. Invest. 90:2284]. The human PAP I protein is the same size as the rat PAP I protein (175 amino acids) and these two proteins share 71% amino acid identity, including conservation of 7 cystine residues. Expression of the human PAP I mRNA is increased in necrohemorrhagic pancreatitis. Serum levels of human PAP I were found to be near
15 background levels in normal individuals; in individuals suffering from acute pancreatitis or acute exacerbations of chronic pancreatitis, human PAP I levels increased 24-140 times the background level [Orelle *et al.* (1992), *supra*]. Thus, human PAP I appears to serve as a marker of acute pancreatitis.

The human PAP I gene is also referred to as the HIP gene [Lasserre *et al.* (1992) Cancer
20 Res. 52:5089]. The HIP gene was identified by differential screening of a human primary liver cancer library. The human PAP I/HIP gene is not expressed in normal adult or fetal liver; expression of PAP I/HIP is limited to pancreas and small intestine in normal tissues. Thus, the ectopic expression of PAP I/HIP is associated with tumorigenesis in the liver.

Proteins expressed by the reg/PSP multigene family represent an important family of
25 proteins which are involved in maintenance of proper pancreatic function as well as in regulating cell growth. Discovery of new molecules related to or in the mammalian reg/PSP multigene family is useful for the development of new diagnostic or therapeutic compositions.

DISCLOSURE OF THE INVENTION

The present invention discloses a novel human reg protein hereinafter referred to as Reg
30 protein I γ (Reg I γ), which shares features with human reg proteins I α and I β (Reg I α and Reg I β) and rat lithostathine as well as other members of the reg/PSP multigene family which are involved in maintenance of proper pancreatic function as well as the regulation of cell growth and

development, including metastatic potential. Accordingly, the invention provides a substantially polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. In an alternative embodiment, the present invention provides fragments of isolated (*i.e.*, substantially purified) human Reg I γ of at least 10 amino acid residues in length. The invention further
5 contemplates fragments of isolated human Reg I γ of at least 25 amino acids, of at least 50 amino acids, at least 100 amino acids, and at least 150 amino acids in length. The invention specifically contemplates secretory (*i.e.*, the signal peptide is cleaved) and nonsecretory (*i.e.*, signal peptide remains) forms of a substantially purified human Reg I γ as well as any proteolytic fragments thereof.

10 The present invention further provides an isolated polynucleotide sequence encoding a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. In a preferred embodiment, the isolated polynucleotide comprises at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof. In another preferred embodiment, the present invention provides polynucleotides comprising fragments of SEQ ID NO:2 having a length
15 greater than 30 nucleotides. The invention further contemplates fragments of this polynucleotide sequence (*i.e.*, SEQ ID NO:2) that are at least 50 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. The invention specifically contemplates polynucleotides encoding the secretory (*i.e.*, the signal peptide is cleaved) and nonsecretory (*i.e.*, signal peptide remains) forms of human Reg I γ as well as any proteolytic fragments thereof.

20 In yet another embodiment, the present invention provides polynucleotide sequences comprising the complement of the nucleic acid sequence of SEQ ID NO:2 or variants thereof; these complementary nucleic acid sequences may comprise the complement of the entire nucleic acid sequence of SEQ ID NO:2 or fragments thereof.

In another embodiment, the present invention provides a polynucleotide sequence that
25 hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO:2.

The invention further relates to the nucleic acid sequence encoding human Reg I γ , oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof.

The present invention also provides a method for detecting the presence of polynucleotide
30 sequences encoding at least a portion of human Reg I γ in a biological sample, comprising the steps of: a) providing: i) a biological sample suspected of containing nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2; ii) the polynucleotide of SEQ ID NO:2, or a

fragment thereof; b) combining the biological sample with the polynucleotide under conditions such that a hybridization complex is formed between the nucleic acid and the polynucleotide; and c) detecting the hybridization complex. The method of the present invention is not limited by the nature of the nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2. In a
5 preferred embodiment, the nucleic acid is ribonucleic acid (RNA) and the detection of a hybridization complex between SEQ ID NO:2 and the RNA correlates with expression of the polynucleotide of SEQ ID NO:2 in the biological sample. In another preferred embodiment, the nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2 is deoxyribonucleic acid (DNA) and the detection of a hybridization complex between the DNA in a sample and SEQ
10 ID NO:2 is performed under conditions that permit the detection of alterations (*e.g.*, deletions, translocations, insertions, point mutations, etc.) in the polynucleotide of SEQ ID NO:2 in the biological sample.

The present invention further provides an antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2. In another
15 embodiment, the present invention provides a pharmaceutical composition comprising an antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2 and a pharmaceutically acceptable excipient.

In another embodiment, the present invention provides an isolated polynucleotide comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof
20 contained on a recombinant expression vector. In yet another embodiment, the expression vector containing the polynucleotide sequence is contained within a host cell. The invention is not limited by the nature of the host cell employed. For example, the host cell may be an *E. coli* cell, a yeast cell, an insect cell, a mammalian cell, etc.

The present invention further provides a method for producing a polypeptide comprising
25 the amino acid sequence of SEQ ID NO:1, the method comprising the steps of: a) culturing the host cell containing an expression vector containing an isolated polynucleotide comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

30 In another embodiment, the present invention provides a pharmaceutical composition comprising a substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

The present invention also provides a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1. The present invention further provides a pharmaceutical composition comprising a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid
5 sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

The present invention also provides a method for detecting the expression of human Reg I γ in a biological sample comprising the steps of: a) providing: i) a biological sample suspected of expressing human Reg I γ protein; and ii) a purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1; b)
10 combining the biological sample and the antibody under conditions such that an antibody:protein complex is formed; and c) detecting the complex wherein the presence of the complex correlates with the expression of the protein in the biological sample.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the amino acid sequence (SEQ ID NO:1) and nucleic acid
15 sequence (SEQ ID NO:2) of human Reg I γ . The alignment was produced using MacDNAsis™ software (Hitachi Software Engineering Co Ltd, San Bruno, CA).

Figure 2 shows the amino acid sequence alignment between human Reg I γ (SEQ ID NO:1), human Reg I β [GI 474306 (SEQ ID NO:3); Moriizumi *et al.* (1994), *supra*] and rat Reg/lithostathine [GI 393209 (SEQ ID NO:4); Duseti *et al.* (1993), *supra*]. These alignments
20 were produced using the multisequence alignment program of DNASTar™ software (DNASTar Inc, Madison WI).

Figure 3 shows the northern analysis for Incyte Clone 1310334 (SEQ ID NO:2). The northern analysis was produced electronically using the LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto, CA) and shows cDNA libraries in which sequences encoding human
25 Reg I γ were expressed.

Figure 4 shows the hydrophobicity plot for human Reg I γ , SEQ ID NO:1, generated using MacDNAsis software; the X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

Figure 5 shows the isoelectric plot for human Reg I γ , SEQ ID NO:1, generated using
30 MacDNAsis software.

Figure 6 shows the secondary structure for the human Reg I γ , SEQ ID NO:1, generated using MacDNAsis software.

MODES FOR CARRYING OUT THE INVENTION

Definitions

To facilitate understanding of the invention, a number of terms are defined below.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or
5 polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic
origin which may be single- or double-stranded, and represent the sense or antisense strand.
Similarly, "amino acid sequence" as used herein refers to peptide or protein sequence.

"Consensus" as used herein may refer to a nucleic acid sequence 1) which has been
resequenced to resolve uncalled bases, 2) which has been extended using XL-PCR (Perkin Elmer,
10 Norwalk CT) in the 5' or the 3' direction and resequenced, 3) which has been assembled from
the overlapping sequences of more than one Incyte clone GCG Fragment Assembly System,
(GCG, Madison WI), or 4) which has been both extended and assembled.

"Peptide nucleic acid" ("PNA") as used herein refers to a molecule which comprises an
oligomer to which an amino acid residue, such as lysine, and an amino group have been added.
15 These small molecules, also designated anti-gene agents, stop transcript elongation by binding to
their complementary strand of nucleic acid [Nielsen PE *et al.* (1993) *Anticancer Drug Des*
8:53-63].

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which
one or more nucleotides or amino acid residues, respectively, are absent.

20 An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which
has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as
compared to, for example, the naturally occurring human Reg I γ .

A "substitution" results from the replacement of one or more nucleotides or amino acids
by different nucleotides or amino acids, respectively.

25 As used herein the "reg/PSP multigene family" refers to genes encoding any of the
following proteins: regenerating protein, reg protein, regI α protein, regI β , lithostathine, islet cell
regeneration factor (ICRF), pancreatic stone protein (PSP), pancreatic thread protein (PTP), HIP
protein, pancreatitis-associated protein (PAP) and the novel Reg I γ of the present invention, as
well as other genes which encode proteins sharing at least 21% identity with the listed proteins.

30 Members of the reg/PSP multigene family share a number of features including expression in the
pancreas and the presence of sequences conserved among the CRD of C-type lectins. On the
amino acid level, members of the reg/PSP multigene family share about 30-87% identity. Protein

sequences comprising typical amino acid compositions (*i.e.*, amino acids are present at their observed normal frequencies) which share an identity of greater than 20% are defined as "homologous" or related proteins; this assumes that only a limited number of insertions and deletions are made to align the sequences being compared [Creighton, *Proteins, Structure and Molecular Properties*, 2nd ed., W.H. Freeman, NY, pp. 108-109 (1993)].

As used herein, "Reg I γ " or "Reg protein I γ " refers to the amino acid sequence of substantially purified Reg I γ obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic or recombinant.

10 A "variant" of Reg I γ is defined as an amino acid sequence differs by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, *e.g.*, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, *e.g.*, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (*i.e.*,
15 additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTar software. Furthermore, as described herein, certain amino acid residues which are highly conserved among mammalian Reg and PAP proteins are located within the CRD of these C-type lectins. It is
20 preferred that these conserved residues not be substituted, inserted or deleted when producing variants of human Reg I γ .

The term "biologically active" refers to a Reg I γ molecule having structural, regulatory or biochemical functions of a naturally occurring Reg I γ . Likewise, "immunologically active" defines the capability of the natural, recombinant or synthetic Reg I γ , or any oligopeptide
25 thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "derivative" as used herein refers to the chemical modification of a nucleic acid encoding Reg I γ or the encoded Reg I γ . Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a
30 polypeptide which retains essential biological characteristics of natural human Reg I γ .

As used herein, the term "substantially purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated,

and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. An "isolated polynucleotide" is therefore a substantially purified polynucleotide.

"Amplification" is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction technologies well known in the art [Dieffenbach CW and GS Dveksler (1995) *PCR Primer, a Laboratory Manual*, Cold Spring Harbor Press, Plainview NY].

The term "hybridization" as used herein refers to any process by which a strand of nucleic acid joins with a complementary strand through base pairing.

As used herein the term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (*e.g.*, C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid support [*e.g.*, a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in *in situ* hybridization, including FISH (fluorescent *in situ* hybridization)].

As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (*i.e.*, a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence "A-G-T," is complementary to the sequence "T-C-A." Complementarity may be "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.

The term "homology" when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely

complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

Low stringency conditions comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄•H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

High stringency conditions comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄•H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42°C when a probe of about 500 nucleotides in length is employed.

The art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions. The term "hybridization" as used herein includes "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" [Coombs J (1994) *Dictionary of Biotechnology*, Stockton Press, New York NY].

"Stringency" typically occurs in a range from about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. Under "stringent conditions" SEQ ID NO:2 or fragments thereof will hybridize to its exact complement and closely related sequences. The stringent conditions are chosen such that SEQ ID NO:2 or fragments thereof will hybridize to sequences encoding human Reg I γ but not to sequences encoding human Reg I β (*i.e.*, SEQ ID NO:3 or its RNA equivalents) or rat Reg/lithostathine (*i.e.*, SEQ ID NO:4 or its RNA equivalents). When fragments of SEQ ID NO:2 are employed in hybridization reactions, the stringent conditions include the choice of fragments of SEQ ID NO:2 to be used. Fragments of SEQ ID NO:2 which contain unique sequences (*i.e.*, regions which are either non-homologous to or which contain less than about 50% homology or complementarity with SEQ ID NOS:5 or 6) are preferentially employed. SEQ ID NOS:5 and 6 represent DNA sequences encoding the human regI β and rat reg/lithostathine proteins, respectively.

As used herein, the term "antisense" is used in reference to RNA sequences which are complementary to a specific RNA sequence (*e.g.*, mRNA). Antisense RNA may be produced by any method, including synthesis by splicing the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a coding strand. Once introduced into a cell, this transcribed strand combines with natural mRNA produced by the cell to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation. In this manner, mutant phenotypes may be generated. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. The designation (-) (*i.e.*, "negative") is sometimes used in reference to the antisense strand, with the designation (+) sometimes used in reference to the sense (*i.e.*, "positive") strand.

As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:2" encompasses the full-length human Reg I γ protein and fragments thereof.

The term "antigenic determinant" as used herein refers to that portion of a molecule that makes contact with a particular antibody (*i.e.*, an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the

production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (*i.e.*, the immunogen used to elicit the immune response) for binding to an antibody.

5 The terms "specific binding" or specifically binding" when used in reference to the interaction of an antibody and a protein or peptide means that the interaction is dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the protein; in other words the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a
10 protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample" as used herein is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding human Reg I γ may comprise a cell, chromosomes isolated from a cell (*e.g.*, a spread of metaphase chromosomes), genomic DNA (in solution or
15 bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for Northern blot analysis), cDNA (in solution or bound to a solid support) and the like. A sample suspected of containing a protein may comprise a cell, a portion of a tissue, an extract containing one or more proteins and the like.

The term "correlates with expression of a polynucleotide" as used herein indicates that the
20 detection of the presence of ribonucleic acid complementary to SEQ ID NO:2 by hybridization assays is indicative of the presence of mRNA encoding human Reg I γ in a sample and thereby correlates with expression of the Reg I γ mRNA from the gene encoding Reg I γ .

"Alterations in the polynucleotide of SEQ ID NO:2" as used herein comprise any alteration in the sequence of polynucleotides encoding human Reg I γ including deletions,
25 insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes human Reg I γ [*e.g.*, by alterations in pattern of restriction enzyme fragments capable of hybridizing to SEQ ID NO:2 (RFLP analysis), the inability of a selected fragment of SEQ ID NO:2 to hybridize to a sample of genomic DNA (*e.g.*, using allele-specific oligonucleotide probes), improper or
30 unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the *reg I γ* gene (*e.g.*, using FISH to metaphase chromosomes spreads, etc.)].

Preferred Embodiments

Given the role C-type lectins play in regulating cell growth and development, the discovery of new molecules related to or in the C-type lectin gene family, and in the human reg/PSP multigene family in particular, is useful for developing diagnostic or therapeutic compositions directed at detecting or preventing neoplasia and/or metastasis. In addition, overexpression of Reg proteins is seen in Alzheimer's disease and thus novel human *reg* genes are useful for developing diagnostic or therapeutic compositions directed at detection and treatment of the neurodegenerative changes associated with Alzheimer's disease and other disorders of the central nervous system (*e.g.*, Down's syndrome).

As aberrant (*e.g.*, ectopic) expression of members within the reg/PSP gene family is associated with tumorigenesis, the discovery of new molecules related to or in the reg/PSP gene family is useful for developing diagnostic or therapeutic compositions directed at a variety of tumors. Furthermore, new molecules related to or in the reg/PSP gene family are useful for developing diagnostic or therapeutic compositions directed at correcting diseases associated with the overexpression or underexpression of reg/PSP proteins.

The present invention relates to a novel human Reg I γ which was initially identified among the partial cDNAs from a fetal colon library (COLNFET02) and to the use of the disclosed nucleic acid and amino acid sequences in the study, diagnosis, prevention and treatment of disease.

The nucleic acid sequence encoding a portion of the novel human Reg I γ protein was identified in Incyte Clone 1310334 through a computer-generated search for amino acid sequence alignments. The nucleic acid sequence, SEQ ID NO:2, disclosed herein, encodes the amino acid sequence, SEQ ID NO:1, human Reg I γ (Figure 2). The full length cDNA was assembled from Incyte Clones 774137; 775162; 793926; 794035; 794837; 794931; 798309; 815300; 816795; 817375; 1310334; and 1436720 from the LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto, CA).

The human Reg I γ of the present invention is here described as having 158 amino acid residues, a number of which are residues shown to be conserved among mammalian Reg and PAP proteins and which are conserved among the CRD of C-type animal lectins. The conserved sequence motif found in C-type CRDs is described by Drickamer [Curr. Opin. Struc. Biol. (1993) 3:393] and a version of this motif is found in the PROSITE database as the C-type lectin domain

signature (CTL). Sequences corresponding to the CTL within the human Reg I γ of the present invention include G₃₃, C₅₈, G₉₅, D₉₈, W₁₁₈, C₁₂₉, A₁₃₀, W₁₄₁, C₁₄₆, F₁₅₂ and C₁₅₄.

The amino-terminal 23 residues of the human Reg I γ of the present invention are hydrophobic and likely represent a signal sequence, a feature common to mammalian Reg and
5 PAP proteins.

The human Reg I γ of the present invention contains seven cysteine residues (C₁₄, C₃₀, C₄₁, C₅₈, C₁₂₉, C₁₄₆ and C₁₅₄); six of these seven cysteine residues (*i.e.*, C₃₀, C₄₁, C₅₈, C₁₂₉, C₁₄₆ and C₁₅₄) are conserved between the human Reg I γ and RegI β and rat Reg/lithostathine proteins (see alignment shown in Figure 2; residues are numbered according to SEQ ID NO:1). The human
10 Reg I γ of the present invention has one potential N-linked glycosylation sites (*i.e.*, Asn-X-Ser/Thr) (*i.e.*, N₅₀). The human Reg I γ of the present invention contains numerous potential O-linked glycosylation sites (*i.e.*, serine and threonine residues). Other human Reg proteins have been shown to be glycosylated [Watanabe *et al.* (1990), *supra*]. In addition, the human Reg I γ of the present invention contains potential phosphorylation sites (*i.e.*, typically the hydroxyl groups
15 of serine, threonine and tyrosine residues although asparagine, histidine and lysine residues may also be phosphorylated). Serine residues preceded by one or two basic residues are often phosphorylated by Ser/Thr kinases [Creighton, *Proteins, Structure and Molecular Properties*, 2nd ed., W.H. Freeman, NY, pp. 96-97 (1993)]; the novel human Reg I γ protein disclosed herein contains four such potential phosphorylation sites (*i.e.*, S₃₉, S₈₉, S₁₁₇, and S₁₂₂). Other human Reg
20 proteins (*e.g.*, human reg/lithostathine/PSP) have been shown to be phosphoglycoproteins containing two to three phosphate groups [Multigener *et al.* (1985) *Gastroenterology* 89:387].

The Human Reg I γ Coding Sequences

The nucleic acid and deduced amino acid sequences of human Reg I γ are shown in Figures 1A and 1B. In accordance with the invention, any nucleic acid sequence which encodes
25 human Reg I γ can be used to generate recombinant molecules which express human Reg I γ . In a specific embodiment described herein, a partial sequence encoding human Reg I γ was first isolated as Incyte Clone 1310334 from a fetal colon cDNA library (COLNFET02).

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of human Reg I γ -encoding nucleotide sequences, some bearing
30 minimal homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These

combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence encoding naturally occurring human Reg I γ , and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode human Reg I γ and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring sequence under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding human Reg I γ or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding human Reg I γ and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater or a shorter half-life, than transcripts produced from the naturally occurring sequence.

It is now possible to produce a DNA sequence, or portions thereof, encoding human Reg I γ and its derivatives entirely by synthetic chemistry, after which the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding human Reg I γ or any portion thereof.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of Figure 1B under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (1987, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol 152, Academic Press, San Diego CA) incorporated herein by reference, and may be used at a defined "stringency".

Altered nucleic acid sequences encoding human Reg I γ which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent human Reg I γ . The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent human Reg I γ . Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the

biological activity of human Reg I γ is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine
5 phenylalanine, and tyrosine.

Included within the scope of the present invention are alleles encoding human Reg I γ . As used herein, an "allele" or "allelic sequence" is an alternative form of the nucleic acid sequence encoding human Reg I γ . Alleles result from a mutation, *i.e.*, a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may
10 or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing are well known in the art and employ such enzymes as the
15 Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH), *Taq* DNA polymerase (Perkin Elmer, Norwalk CT), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200
20 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer).

Extending The Polynucleotide Sequence

The polynucleotide sequence encoding human Reg I γ may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as
25 promoters and regulatory elements. Gobinda *et al.* (1993; PCR Methods Applic 2:318-22) describe "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker
30 primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia T *et al.* (1988) Nucleic Acids Res 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom M *et al.* (1991) PCR Methods Applic 1:111-19), a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA, may also be used. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

Another method which may be used to retrieve unknown sequence is walking PCR (Parker JD *et al.* (1991) Nucleic Acids Res 19:3055-60), a method for targeted gene walking. Alternatively, PCR, nested primers, PromoterFinder™ (Clontech, Palo Alto CA) and PromoterFinder libraries can be used to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

Capillary electrophoresis may be used to analyze either the size or confirm the nucleotide sequence in sequencing or PCR products. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (*e.g.*, Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small

pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp of M13 phage DNA in 30 min has been reported [Ruiz-Martinez MC *et al.* (1993) Anal Chem 65:2851-8].

Expression Of The Nucleotide Sequence

5 In accordance with the present invention, polynucleotide sequences which encode human Reg I γ , fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of human Reg I γ in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to
10 clone and express human Reg I γ . As will be understood by those of skill in the art, it may be advantageous to produce human Reg I γ -encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host [Murray E *et al.* (1989) Nuc Acids Res 17:477-508] can be selected, for example, to increase the rate of human Reg I γ expression or to produce recombinant RNA transcripts having desirable properties, such
15 as a longer or a shorter half-life, than transcripts produced from naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered in order to alter a human Reg I γ -encoding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, *e.g.*,
20 site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc.

In another embodiment of the invention, a natural, modified or recombinant human Reg I γ -encoding sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of human Reg I γ activity, it may be
25 useful to encode a chimeric human Reg I γ protein that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a human Reg I γ and the heterologous protein sequence, so that the human Reg I γ may be cleaved and substantially purified away from the heterologous moiety.

In an alternate embodiment of the invention, the sequence encoding human Reg I γ may
30 be synthesized, whole or in part, using chemical methods well known in the art [see Caruthers MH *et al.* (1980) Nuc Acids Res Symp Ser 215-23, Horn T *et al.* (1980) Nuc Acids Res Symp Ser 225-32, etc.]. Alternatively, the protein itself could be produced using chemical methods to

synthesize a human Reg I γ amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques [Roberge JY *et al.* (1995) Science 269:202-204] and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the
5 manufacturer.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography [*e.g.*, Creighton (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co, New York NY]. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure;
10 Creighton, *supra*). Additionally the amino acid sequence of human Reg I γ , or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

Expression Systems

In order to express a biologically active human Reg I γ , the nucleotide sequence encoding
15 human Reg I γ or its functional equivalent, is inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing a human Reg I γ -encoding sequence and appropriate transcriptional
20 or translational controls. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination or genetic recombination. Such techniques are described in Sambrook *et al.* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview NY and Ausubel FM *et al.* (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY.

25 A variety of expression vector/host systems may be utilized to contain and express a human Reg I γ -encoding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transfected with virus expression vectors
30 (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmid); or animal cell systems.

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3' and 5' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla CA) or pSport1 (Gibco BRL) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO; and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding human Reg I γ , vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for human Reg I γ . For example, when large quantities of human Reg I γ are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding human Reg I γ may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors [Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509]; and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel *et al.* (*supra*) and Grant *et al.* (1987) Methods in Enzymology 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding human Reg I γ may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV [Brisson *et al.* (1984) *Nature* 310:511-514] may be used alone or in combination with the omega leader sequence from TMV [Takamatsu *et al.* (1987) *EMBO J* 6:307-311]. Alternatively, plant promoters such as the small subunit of RUBISCO [Coruzzi *et al.* (1984) *EMBO J* 3:1671-1680; Broglie *et al.* (1984) *Science* 224:838-843]; or heat shock promoters [Winter J and Sinibaldi RM (1991) *Results Probl Cell Differ* 17:85-105] may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S or Murry LE in *McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill New York NY, pp 191-196 or Weissbach and Weissbach (1988) *Methods for Plant Molecular Biology*, Academic Press, New York NY, pp 421-463.

An alternative expression system which could be used to express human Reg I γ is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequence encoding human Reg I γ may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the sequence encoding human Reg I γ will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which human Reg I γ is expressed [Smith *et al.* (1983) *J Virol* 46:584; Engelhard EK *et al.* (1994) *Proc Natl Acad Sci* 91:3224-7].

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a sequence encoding human Reg I γ may be ligated into an adenovirus transcription/ translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing in infected host cells [Logan and Shenk (1984) *Proc Natl Acad Sci* 81:3655-59]. In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a sequence encoding human Reg I γ . These signals include the ATG initiation codon and adjacent sequences. In cases where the sequence encoding human Reg I γ , its initiation codon and upstream sequences are inserted into the most appropriate expression vector, no additional

translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon, and termination codons must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure translation of the entire insert. Exogenous translational

5 elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use [Scharf D *et al.* (1994) *Results Probl Cell Differ* 20:125-62; Bittner *et al.* (1987) *Methods in Enzymol* 153:516-544].

In addition, a host cell strain may be chosen for its ability to modulate the expression of
10 the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO (ATCC CCL 61 and CRL 9618), HeLa (ATCC CCL
15 2), MDCK (ATCC CCL 34 and CRL 6253), HEK 293 (ATCC CRL 1573), WI-38 (ATCC CCL 75) (ATCC: American Type Culture Collection, Rockville, MD), etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is
20 preferred. For example, cell lines which stably express human Reg I γ may be transformed using expression vectors which contain endogenous expression elements, and may also contain viral origins of replication and a selectable marker gene; the selectable marker gene may be located on the same vector as the Reg I γ -encoding sequences or may be located on a separate vector which contains sequences which permit expression of the selectable marker gene. Following the
25 introduction of the vector(s), cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transfected cells can be proliferated using tissue culture techniques appropriate to the cell type.

30 Any number of selection systems may be used to recover transfected cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy I *et al.* (1980) *Cell* 22:817-23)

genes which can be employed in tk- or apt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate [Wigler M *et al.* (1980) Proc Natl Acad Sci 77:3567-70]; *npt*, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin F *et al.* (1981) J Mol Biol 150:1-14] and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine [Hartman SC and RC Mulligan (1988) Proc Natl Acad Sci 85:8047-51]. Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes CA *et al.* (1995) Methods Mol Biol 55:121-131].

Identification Of Transformants Containing The Polynucleotide Sequence

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the sequence encoding human Reg I γ is inserted within a marker gene sequence, recombinant cells containing the sequence encoding human Reg I γ can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence encoding human Reg I γ under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem sequence as well.

Alternatively, host cells which contain the coding sequence for human Reg I γ and express human Reg I γ may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding human Reg I γ can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the sequence encoding human Reg I γ . Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the nucleic acid sequence to detect transformants containing DNA or RNA encoding human Reg I γ . As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about

60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression of human Reg I γ , using either polyclonal or monoclonal antibodies specific for the protein are known in the art.

- 5 Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on human Reg I γ is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R *et al.* (1990, *Serological Methods a Laboratory Manual*, APS Press, 10 St Paul MN) and Maddox DE *et al.* (1983, *J Exp Med* 158:1211).

- A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the 15 human Reg I γ -encoding sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

- A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison 20 WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like.

Purification Of Human Reg I γ

- 25 Host cells transformed with a nucleotide sequence encoding human Reg I γ may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing human Reg I γ -encoding sequence can be 30 designed with signal sequences which direct secretion of human Reg I γ through a prokaryotic or eukaryotic cell membrane; the naturally occurring Reg I γ signal sequence may be utilized or alternatively, heterologous signal sequences derived from prokaryotic or eukaryotic genes may be

employed. Further, the art understands that where secretion of human Reg I γ is not desired, sequences encoding the naturally-occurring human Reg I γ signal sequence are not employed on expression vectors containing human Reg I γ gene sequences.

Human Reg I γ may also be expressed as a recombinant protein with one or more
5 additional polypeptide domains added to facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle,
10 WA). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and human Reg I γ is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding human Reg I γ and nucleic acid sequence encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage site. The histidine residues
15 facilitate purification while the enterokinase cleavage site provides a means for purifying human Reg I γ from the fusion protein. Literature pertaining to vectors containing fusion proteins is available in the art [*see*, for example, Kroll DJ *et al.* (1993) DNA Cell Biol 12:441-53].

In addition to recombinant production, fragments of human Reg I γ may be produced by direct peptide synthesis using solid-phase techniques [cf Stewart *et al.* (1969) *Solid-Phase*
20 *Peptide Synthesis*, WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of human Reg I γ may be chemically
25 synthesized separately and combined using chemical methods to produce the full length molecule.

Uses Of Human Reg I γ

The rationale for use of the nucleotide and peptide sequences disclosed herein is based in part on the chemical and structural homology among the novel human Reg I γ protein and the
30 human Reg I β [GI 474306; Moriizumi *et al.* (1994), *supra*] and rat reg/lithostathine proteins [GI 393209; Duseti *et al.* (1993), *supra*]. In addition, the novel human Reg I γ protein shares structural features with several other proteins in the reg/PSP multigene family, including amino

acid sequences which are conserved among the CRD of C-type lectins. Lectins are involved in a variety of cellular functions including cell-cell and cell-matrix interactions; aberrant expression of some lectins is associated with tumorigenesis and/or metastasis. Indeed, aberrant expression of some members of the reg/PSP multigene family is associated with a variety of disease states.

5 For example, overexpression of human regI α is observed in human colon and rectal tumors [Watanabe *et al.* (1990), *supra*]. Overexpression of human regI α is observed in the brains of Alzheimer's patients and in the brains of middle-age Down's syndrome patients [de la Monte *et al.* (1990), *supra*]. Brains from these patients show an accumulation of paired helical filaments which are similar to the filamentous bundles formed by regI α protein *in vitro* (hence some
10 investigators termed this protein pancreatic thread protein) [Gross *et al.* (1985) Proc. Natl. Acad. Sci. USA 82:5627]. Expression of the human PAP I/HIP gene in adult liver is associated with liver cancer; PAPI/HIP is not expressed in normal adult or fetal liver [Lasserre *et al.* (1992), *supra*]. PAP proteins are overexpressed in the pancreas of individuals suffering from acute pancreatitis and thus serve as markers for this disease [Orelle *et al.* (1992), *supra*].

15 Proteins within the reg/PSP multigene family are expressed in the pancreas. As demonstrated herein, the human Reg I γ of the present invention, like other reg/PSP genes, is expressed in pancreas. In addition, as shown herein, human Reg I γ is expressed most abundantly in human ovary and in ovarian tumor tissue with lower levels of expression in colon tissue. As other investigations failed to examine the expression of reg/PSP family members in ovarian
20 tissue, it is not known whether the abundant expression of human RegI γ in the ovary is a feature unique to this novel gene or whether this is a characteristic shared by other reg/PSP family members.

Ectopic expression or the perturbations of the normal pattern of expression of reg/PSP proteins has been shown to be associated with a variety of disease states, including tumors and
25 neurodegenerative diseases; therefore, the human Reg I γ nucleic and amino acid sequences of the present invention are useful in the development of diagnostics for the detection of tumors and other diseases. The nucleotide sequence may be used in hybridization or PCR technologies to diagnose the induced expression of Reg I γ sequences early in the disease process. Likewise the protein can be used to produce antibodies useful in ELISA assays or a derivative diagnostic
30 format (as discussed in detail below).

In order to provide a basis for diagnosis, normal or standard values for human Reg I γ mRNA expression must be established. This is accomplished by quantitating the amount of Reg

I γ mRNA in tissues taken from normal subjects, either animal or human, with nucleic probes derived from the Reg I γ sequences provided herein (either DNA or RNA forms) using techniques which are well known in the art (*e.g.*, Southern blots, Northern blots, dot or slot blots). The standard values obtained from normal samples may be compared with values obtained from
5 samples from subjects potentially affected by disease (*e.g.*, tumors, Alzheimer's, chronic calcifying pancreatitis or other disorders of the pancreas). Deviation between standard and subject values establishes the presence of a disease state.

The nucleotide sequence encoding human Reg I γ is useful when placed in an expression vector for making quantities of protein for therapeutic use. The antisense nucleotide sequence of
10 the human RegI γ gene is potentially useful in vectors designed for gene therapy directed at neoplasia including metastases. Additionally, the inhibition of human Reg I γ expression may be useful in alleviating the neurodegenerative changes associated with disorders such as Alzheimer's disease. Alternatively, the human Reg I γ -encoding nucleotide sequence may be used to direct the expression of human Reg I γ in situations where it is desirable to increase the amount of human
15 Reg I γ (*e.g.*, for disorders associated with low or nonexistent level of expression of Reg I γ or to induce or aid in the regeneration of pancreatic islet cells). Even the transient expression or delivery of human Reg I γ to cells and tissues may be therapeutic. The expression of reg/PSP proteins is important for proper pancreatic function and therefore the ability to increase the level of expression of human Reg I γ in patients which fail to express normal levels of Reg I γ in the
20 pancreas is therapeutic.

Human Reg I γ Antibodies

Human Reg I γ -specific antibodies are useful for the diagnosis and treatment of conditions and diseases associated with expression of human Reg I γ (including the overexpression and the absence of expression). Such antibodies include, but are not limited to, polyclonal, monoclonal,
25 chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, *i.e.*, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics.

Human Reg I γ protein to be used for antibody induction need not retain biological activity; however, the protein fragment, or oligopeptide must be antigenic. Peptides used to
30 induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids. Preferably, they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small,

naturally occurring molecule. Short stretches of human Reg I γ amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc
5 may be immunized by injection with human Reg I γ or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and
10 dinitrophenol. BCG (*Bacillus Calmette-Guerin*) and *Corynebacterium parvum* are potentially useful adjuvants.

Monoclonal antibodies to human Reg I γ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and
15 Milstein (1975 *Nature* 256:495-497), the human B-cell hybridoma technique (Kosbor *et al.* (1983) *Immunol Today* 4:72; Cote *et al.* (1983) *Proc Natl Acad Sci* 80:2026-2030) and the EBV-hybridoma technique [Cole *et al.* (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss Inc, New York NY, pp 77-96].

In addition, techniques developed for the production of "chimeric antibodies", the splicing
20 of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used [Morrison *et al.* (1984) *Proc Natl Acad Sci* 81:6851-6855; Neuberger *et al.* (1984) *Nature* 312:604-608; Takeda *et al.* (1985) *Nature* 314:452-454]. Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,778) can be adapted to produce human Reg I γ -specific single chain
25 antibodies.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi *et al.* (1989, *Proc Natl Acad Sci* 86:3833-3837), and Winter G and Milstein C (1991; *Nature* 349:293-299).

30 Antibody fragments which contain specific binding sites for human Reg I γ may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments

which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity [Huse WD *et al.* (1989) Science 256:1275-1281].

A variety of protocols for competitive binding or immunoradiometric assays using either
5 polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between human Reg I γ and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific human Reg I γ protein is preferred, but a competitive binding assay may also be
10 employed. These assays are described in Maddox DE *et al.* (1983, J Exp Med 158:1211).

Diagnostic Assays Using Human Reg I γ Specific Antibodies

Particular human Reg I γ antibodies are useful for the diagnosis of conditions or diseases characterized by expression of human Reg I γ or in assays to monitor patients being treated with human Reg I γ , its fragments, agonists or inhibitors (including antisense transcripts capable of
15 reducing expression of human Reg I γ). Diagnostic assays for human Reg I γ include methods utilizing the antibody and a label to detect human Reg I γ in human body fluids or extracts of cells or tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter
20 molecules are known, several of which were described above.

A variety of protocols for measuring human Reg I γ , using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal
25 antibodies reactive to two non-interfering epitopes on human Reg I γ is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE *et al.* (1983, J Exp Med 158:1211).

In order to provide a basis for diagnosis, normal or standard values for human Reg I γ expression must be established. This is accomplished by combining body fluids or cell extracts
30 taken from normal subjects, either animal or human, with antibody to human Reg I γ under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes

containing known quantities of human Reg I γ with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease (*e.g.*, metastases, Alzheimer's disease, chronic calcifying pancreatitis or other disorders of the pancreas). Deviation
5 between standard and subject values establishes the presence of a disease state.

Drug Screening

Human Reg I γ , its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a
10 cell surface, or located intracellularly. The formation of binding complexes, between human Reg I γ and the agent being tested, may be measured.

Another technique for drug screening which may be used for high throughput screening of compounds having suitable binding affinity to the human Reg I γ is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO Application
15 84/03564, published on September 13, 1984, and incorporated herein by reference. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with fragments of human Reg I γ and washed. Bound human Reg I γ is then detected by methods well known in the art. Substantially purified human Reg I γ can also be coated directly onto plates for
20 use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding human Reg I γ specifically compete with a test compound for binding human Reg I γ . In this manner, the antibodies can be used to detect the
25 presence of any peptide which shares one or more antigenic determinants with human Reg I γ .

Uses Of The Polynucleotide Encoding Human Reg I γ

A polynucleotide sequence encoding human Reg I γ or any part thereof may be used for diagnostic and/or therapeutic purposes. For diagnostic purposes, the sequence encoding human Reg I γ of this invention may be used to detect and quantitate gene expression in biopsied tissues
30 in which human Reg I γ may be expressed. The diagnostic assay is useful to distinguish between absence, presence, and excess expression of human Reg I γ and to monitor regulation of human

Reg I γ levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs.

Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding human Reg I γ or closely related molecules. The specificity of the probe, whether it is made from a highly specific region, *e.g.*, 10 unique nucleotides in the 5' regulatory region, or a less specific region, *e.g.*, especially in the 3' region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring human Reg I γ , alleles or related sequences.

10 Probes may also be used for the detection of related sequences and should preferably contain at least 50% of the nucleotides from any of these human Reg I γ -encoding sequences. The hybridization probes of the subject invention may be derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements and introns of the naturally occurring sequence encoding human Reg I γ . Hybridization probes may be 15 labeled by a variety of reporter groups, including radionuclides such as ^{32}P or ^{35}S , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Other means for producing specific hybridization probes for DNAs include the cloning of nucleic acid sequences encoding human Reg I γ or human Reg I γ derivatives into vectors for the 20 production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

Diagnostic Use

25 Polynucleotide sequences encoding human Reg I γ may be used for the diagnosis of conditions or diseases with which the expression of human Reg I γ is associated. For example, polynucleotide sequences encoding human Reg I γ may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect human Reg I γ expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other 30 membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.

The human Reg I γ -encoding nucleotide sequences disclosed herein provide the basis for assays that detect activation or induction associated with disease (including metastasis); in addition, the lack of expression of human Reg I γ may be detected using the human Reg I γ -encoding nucleotide sequences disclosed herein. The nucleotide sequence may be labeled by
5 methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. If the amount of dye in the
10 biopsied or extracted sample is significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of elevated levels of nucleotide sequences encoding human Reg I γ in the sample indicates the presence of the associated inflammation and/or disease. Alternatively, the loss of expression of human Reg I γ sequences in a tissue which normally expresses human Reg I γ sequences indicates
15 the presence of an abnormal or disease state.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for human Reg I γ expression must be established. This is accomplished by combining body fluids or cell
20 extracts taken from normal subjects, either animal or human, with human Reg I γ , or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of human Reg I γ run in the same experiment where a known amount of substantially purified human Reg I γ is used. Standard values obtained from normal samples may be compared with
25 values obtained from samples from patients affected by human Reg I γ -associated diseases. Deviation between standard and subject values establishes the presence of disease.

Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern. Successive treatment profiles
30 may be used to show the efficacy of treatment over a period of several days or several months.

PCR, may be used and provides additional uses for oligonucleotides based upon the sequence encoding human Reg I γ . Such oligomers are generally chemically synthesized, but

they may be generated enzymatically or produced from a recombinant source. Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'→3') and one with antisense (3'→5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of
5 oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additionally, methods which may be used to quantitate the expression of a particular molecule include radiolabeling [Melby PC *et al.* (1993) J Immunol Methods 159:235-44] or biotinylating [Duplaa C *et al.* (1993) Anal Biochem 229:36] nucleotides, coamplification of a
10 control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition.
15 Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, and the like.

20 **Therapeutic Use**

Based upon its homology to mammalian reg/PSP proteins and its expression profile, the polynucleotide encoding human Reg I γ disclosed herein may be useful in the treatment of diabetes (*e.g.*, to induce regeneration of pancreatic β -cells). In addition, as the overexpression of other reg/PSP proteins has been shown to correlate with tumorigenesis and neurodegeneration,
25 inhibition of human Reg I γ expression may be therapeutic.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences (sense or antisense) to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense
30 of the sequence encoding human Reg I γ . See, for example, the techniques described in Sambrook *et al.* (*supra*) and Ausubel *et al.* (*supra*).

The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use the sequence encoding human Reg I γ as an investigative tool in sense [Yousoufian H and HF Lodish 1993 Mol Cell Biol 13:98-104] or antisense [Eguchi *et al.* (1991) Annu Rev Biochem 60:631-652] regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

Genes encoding human Reg I γ can be turned off by transfecting a cell or tissue with expression vectors which express high levels of a desired human Reg I γ fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the control regions of the sequence encoding human Reg I γ , *i.e.*, the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, *e.g.*, between -10 and +10 regions of the leader sequence, are preferred. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA were reviewed by Gee JE *et al.* [In: Huber BE and BI Carr (1994) *Molecular and Immunologic Approaches*, Futura Publishing Co, Mt Kisco NY].

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of the sequence encoding human Reg I γ .

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following

sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization
5 with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA
10 sequences encoding human Reg I γ . Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible
15 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified
20 forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Methods for introducing vectors into cells or tissues include those methods discussed *infra* and which are equally suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors are introduced into stem cells taken from the patient and clonally propagated for
25 autologous transplant back into that same patient is presented in US Patent Nos. 5,399,493 and 5,437,994, disclosed herein by reference. Delivery by transfection and by liposome are quite well known in the art.

Furthermore, the nucleotide sequences encoding human Reg I γ disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new
30 techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

Detection And Mapping Of Related Polynucleotide Sequences

The nucleic acid sequence encoding human Reg I γ can also be used to generate hybridization probes for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price CM (1993; Blood Rev 7:127-34) and Trask BJ (1991; Trends Genet 7:149-54).

10 The technique of fluorescent *in situ* hybridization (FISH) of chromosome spreads has been described, among other places, in Verma *et al.* (1988) *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York NY. Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 15 1994 Genome Issue of Science (265:1981f). Correlation between the location of a the sequence encoding human Reg I γ on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

20 *In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. A recent example of an STS based map of the human genome was recently published by the Whitehead-MIT Center for Genomic Research [Hudson TJ *et al.* (1995) Science 270:1945-1954]. Often the placement of a gene on the chromosome of another mammalian 25 species such as mouse (Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28, 1995) may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery 30 techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 [Gatti *et al.* (1988) Nature 336:577-580], any sequences mapping to that area may represent associated

or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier or affected individuals.

Pharmaceutical Compositions

5 The present invention relates to pharmaceutical compositions which may comprise nucleotides, proteins, antibodies, agonists, antagonists, or inhibitors, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in
10 combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

Administration Of Pharmaceutical Compositions

Administration of pharmaceutical compositions is accomplished orally or parenterally.

15 Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into
20 preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral
25 administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the
30 mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as

methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

5 Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

10 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty
15 oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection
20 suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable
25 stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Manufacture And Storage

30 The pharmaceutical compositions of the present invention may be manufactured in a manner that known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the invention formulated in a acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of human Reg I γ , such labeling would include amount, frequency and method of administration.

Therapeutically Effective Dose

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, *e.g.*, tumor size and location; age, weight and gender of the patient; 5 diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of 10 about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature. See US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

15 It is contemplated, for example, that human Reg I γ can be used as a therapeutic molecule to induce cell growth (*e.g.*, to induce regeneration of pancreatic β -cells). It is further contemplated that antisense molecules capable of reducing the expression of human Reg I γ can be as therapeutic molecules to treat tumors associated with the aberrant expression of human Reg I γ . Still further it is contemplated that antibodies directed against human Reg I γ and capable of 20 neutralizing the biological activity of human Reg I γ may be used as therapeutic molecules to treat tumors associated with the aberrant expression of human Reg I γ .

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

25 I. COLNFET02 cDNA Library Construction

The COLNFET02 cDNA library was constructed from colon tissue obtained from a 20-week-old Caucasian female fetus. The pregnant mother was treated with erythromycin for seven days in the first trimester for bronchitis (specimen #RU95-10-0739; IIAM, Exton, PA).

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron 30 PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient

temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and DNase treated at 37°C. The RNA extraction was repeated with acid phenol pH 4.7 and precipitated with sodium acetate and ethanol as before. The mRNA was then isolated using the Qiagen Oligotex kit
5 (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013, Gibco/BRL). The commercial plasmid pSPORT 1 (Gibco/BRL) was digested with *EcoRI* restriction enzyme (New England Biolabs, Beverly, MA). The overhanging ends of the plasmid were filled in using
10 Klenow enzyme (New England Biolabs) and 2'-deoxynucleotide 5' triphosphates (dNTPs). The plasmid was self-ligated and transformed into the bacterial host, *E. coli* strain JM 109. An intermediate plasmid produced by the bacteria failed to digest with *EcoRI* confirming the desired loss of the *EcoRI* restriction site.

This intermediate plasmid (pSPORT 1-ΔRI) was then digested with *HindIII* restriction
15 enzyme (New England Biolabs) and the overhang was filled in with Klenow and dNTPs. A 10-mer linker of sequence 5'...CGGAATTCCG...3' was phosphorylated and ligated onto the blunt ends. The product of the ligation reaction was digested with *EcoRI* and self-ligated. Following transformation into JM109 host cells, plasmids were isolated and screened for the digestibility with *EcoRI* but not with *HindIII*. A single colony which met this criteria was designated pINCY
20 1. The plasmid produced by this colony was sequenced and found to contain several copies of the 10-mer linker. These extra linkers did not present a problem as they were eliminated when the vector was prepared for cloning.

The plasmid was tested for its ability to incorporate cDNAs from a library prepared using *NotI* and *EcoRI* restriction enzymes. Several clones were sequenced and a single clone
25 containing an insert of approximately 0.8 kb was selected to prepare a large quantity of the plasmid for library production. After digestion with *NotI* and *EcoRI*, the plasmid and the cDNA insert were isolated on an agarose gel and the vector was purified on a QIAQuick (Qiagen, Inc., Chatsworth, CA) column for use in library construction.

cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01, Pharmacia),
30 and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5α™ competent cells (Cat. #18258-012, Gibco/BRL).

II. Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit for Rapid Extraction Alkaline Lysis Plasmid Minipreps (Catalog #26173, QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, LIFE TECHNOLOGIES™) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4°C.

The cDNAs were sequenced by the method of Sanger *et al.* (1975, J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

Most of the sequences disclosed herein were sequenced according to standard ABI protocols, using ABI kits (Cat. Nos. 79345, 79339, 79340, 79357, 79355). The solution volumes were used at 0.25x - 1.0x concentrations. Some of the sequences disclosed herein were sequenced using different solutions and dyes which, unless otherwise noted, came from Amersham Life Science (Cleveland, OH).

First, stock solutions were prepared with HPLC water. The following solutions were each mixed by vortexing for 2 min: 1) Tris-EDTA (TE) Buffer was prepared by adding 49 ml water to 1 ml 50x Tris-EDTA concentrate, and 2) 10% Reaction Buffer was prepared by adding 45 ml water to 5 ml Concentrated Thermo Sequenase (TS) Reaction Buffer.

Second, 0.2 µM energy transfer (ET) primers were prepared in the following manner. Each primer tube was centrifuged prior to opening to assure that all primer powder was on the bottom of the tube. After each solubilization step, the mixture was vortexed for 2 min and then centrifuged for about 10 sec in a table-top centrifuge. 1 ml of 1x TE was added to each primer powder; adenine and cytosine dissolved primers (5-carboxyrhodamine-6G (R6G) and 6-carboxyfluorescein (FAM), respectively), were diluted with 9 ml 1x TE. Guanine and thymine dyes (N,N,N',N''-tetramethyl 6-carboxyrhodamine (TAM) and 6-carboxy-X-rhodamine (ROX), respectively) were diluted with 19 ml 1x TE.

Next, the sequencing reaction ready mix was prepared as follows: 1) nucleotides A and C (8 ml of each) were added to 6 ml ET primer and 18 ml TS reaction buffer; and 2) nucleotides G and T (8 ml of each) were added to 6 ml ET primer and 18 ml TS reaction buffer.

After vortexing for 2 min and centrifuging for 20 sec, the resulting solution was divided into tubes in volumes of 8 ml per tube in order to make 1x (A,C) and 2x (G,T) solutions.

Prior to thermal cycling, each nucleotide was individually mixed with DNA template in the following proportions:

Reagent	A(μ L)	C(μ L)	G(μ L)	T(μ L)
Reaction Ready Premix	2	2	4	4
DNA Template	1	1	2	2
Total Volume	3	3	6	6

These solutions underwent the following thermal cycling:

1. Rapid thermal ramp to 94°C (94°C for 20 sec)*
2. Rapid thermal ramp to 50°C (50°C for 40 sec)*
3. Rapid thermal ramp to 68°C (68°C for 60 sec)*
- * Steps 1, 2, and 3 were repeated for 15 cycles
4. Rapid thermal ramp to 94°C (94°C for 20 sec)**
5. Rapid thermal ramp to 68°C (68°C for 60 sec)**
- ** Steps 4 and 5 were repeated for 15 cycles
6. Rapid thermal ramp to 4°C and hold until ready to combine.

After thermal cycling, the A, C, G, and T reactions with each DNA template were combined. Then, 50 μ L 100% ethanol was added and the solution was spun at 4°C for 30 min.

The supernatant was decanted and the pellet was rinsed with 100 μ L 70% ethanol. After being spun for 15 min, the supernatant was discarded and the pellet was dried for 15 min under vacuum. The DNA sample was dissolved in 3 μ L of formaldehyde/50 mM EDTA. The resulting samples were loaded on wells in volumes of 2 μ L per well for sequencing in ABI sequencers.

III. Homology Searching of cDNA Clones and Their Deduced Proteins

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT- 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence

comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF *et al.* (1990) J Mol Biol 215:403-10), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

A comparison of the full-length and partial cDNA sequences and the deduced amino acid sequences corresponding to the human *reg Iγ* gene and Reg Iγ protein with known nucleotide and protein sequences in GenBank revealed that the full-length human Reg Iγ cDNA and protein sequences (*i.e.*, SEQ ID NOs:1 and 2) were unique (*i.e.*, not previously identified). Thus, SEQ

ID NO:1 represents the first identified human Reg I γ homolog. This search revealed that the human Reg I γ protein shared some homology with the human Reg I β and rat reg/lithostathine proteins (see alignment in Figure 2); more limited homology with nucleotide sequences encoding the human Reg I β and rat reg/lithostathine proteins was found.

5 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook *et al.*, *supra*).

Analogous computer techniques using BLAST (Altschul SF 1993 and 1990, *supra*) are
10 used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte, Palo Alto CA) (this technique is termed an "electronic northern"). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

15 The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

and it takes into account both the degree of similarity between two sequences and the length of
20 the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript
25 encoding human galectin-8 occurs. Abundance and percentage abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

Electronic northern analysis (Figure 3) revealed that mRNA encoding human Reg I γ
30 (SEQ ID NO:1) was present in libraries generated from the following tissues: ovary (Incyte library: OVARNOT03); ovarian tumor (Incyte library: OVARTUT01); colon (Incyte library: COLNNOT05); pancreas (Incyte library: PANCNOT08); and fetal colon (Incyte library: COLNFET02). This analysis revealed that human Reg I γ transcripts were most abundant in

adult ovary the tissues examined. In addition, this analysis revealed that human Reg Iy transcripts were expressed in tumor tissue (ovarian tumor). The Northern analysis showed that human Reg Iy transcripts were expressed in the pancreas, a feature in common with other members of the reg/PSP multigene family.

5 V. Extension Of The Sequence Encoding Human Reg Iy

The nucleic acid sequence of SEQ ID NO:2 is used to design oligo-nucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' sequence from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers allow the extension
 10 of the know sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest (US Patent Application 08/487,112, filed June 7, 1995, specifically incorporated by reference). The initial primers are designed from the cDNA using OLIGO® 4.06 Primer Analysis Software (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the
 15 target sequence at temperatures about 68°-72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

20 By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

- | | | |
|----|---------|--|
| 25 | Step 1 | 94°C for 1 min (initial denaturation) |
| | Step 2 | 65°C for 1 min |
| | Step 3 | 68°C for 6 min |
| | Step 4 | 94°C for 15 sec |
| | Step 5 | 65°C for 1 min |
| 30 | Step 6 | 68°C for 7 min |
| | Step 7 | Repeat step 4-6 for 15 additional cycles |
| | Step 8 | 94°C for 15 sec |
| | Step 9 | 65°C for 1 min |
| | Step 10 | 68°C for 7:15 min |
| 35 | Step 11 | Repeat step 8-10 for 12 cycles |
| | Step 12 | 72°C for 8 min |

Step 13 4°C (and holding)

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products are selected and cut out of
5 the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc). After recovery of the DNA, Klenow enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is
10 incubated at room temperature for 2-3 hours or overnight at 16°C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook J *et al.*, *supra*). After incubation for one hour at 37°C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook J *et al.*, *supra*) containing 2xCarb. The following day, several colonies are randomly picked from each plate and cultured in
15 150 μ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units
20 of rTth DNA polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

	Step 1	94°C for 60 sec
	Step 2	94°C for 20 sec
25	Step 3	55°C for 30 sec
	Step 4	72°C for 90 sec
	Step 5	Repeat steps 2-4 for an additional 29 cycles
	Step 6	72°C for 180 sec
	Step 7	4°C (and holding)
30	Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid and sequenced.	

VI. Labeling And Use Of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs,
35 genomic DNAs or mRNAs. Although the labeling of oligonucleotides, consisting of about 20

base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [γ - 32 P] adenosine triphosphate (Amersham, Chicago IL) and T4 polynucleotide kinase (DuPont NEN[®], Boston MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 super fine resin column (Pharmacia). A portion containing 10^7 counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (*AseI*, *BglII*, *EcoRI*, *PstI*, *XbaI*, or *PvuII*; DuPont NEN[®]).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR[™] film (Kodak, Rochester NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually.

VII. Antisense Molecules

The sequence encoding human Reg I γ , or any part thereof, is used to inhibit *in vivo* or *in vitro* expression of the naturally occurring sequence. Although use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide complementary to the coding sequence of human Reg I γ as shown in Figures 1A and 1B is used to inhibit expression of the naturally occurring sequence. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A and 1B and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an human Reg I γ -encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the leader and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or early coding sequence of the polypeptide as shown in Figures 1A and 1B.

VIII. Expression Of Human Reg I γ

Expression of the human Reg I γ is accomplished by subcloning the cDNAs into appropriate vectors and transfecting the vectors into host cells. In this case, the cloning vector,

pSport1, previously used for the generation of the cDNA library is used to express human Reg I γ in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful
5 for transcription and a polylinker containing a number of unique restriction sites.

Induction of an isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first seven residues of β -galactosidase, about 5 to 15 residues of linker, and the full length human Reg I γ . The signal sequence provided by the vector directs the secretion of human Reg I γ into the bacterial growth media which can be used
10 directly in the following assay for activity. As the Reg I γ gene contains sequences encoding a signal sequence, these gene sequences may be deleted from the Reg I γ gene when the expression vector employed contains sequences encoding a signal sequence (alternatively, an expression vector which does not provide a signal sequence may be employed in conjunction with the full-length Reg I γ gene).

15 In addition, the human Reg I γ protein may be expressed as a fusion protein containing a histidine tag or GST tag using commercially available expression vectors [e.g., QIAExpress vectors (Qiagen) and pGex vectors (Pharmacia), respectively]. Suitable host cells and conditions for the induction/expression of the desired expression vectors are known to the art and available commercially. Histidine tagged human Reg I γ may be purified from *E. coli* extracts using metal
20 chelation chromatography using commercially available resins [e.g., Ni-NTA Agarose (Qiagen)]. GST-tagged human Reg I γ may be purified from *E. coli* extracts using affinity chromatography using commercially available resins [e.g., glutathione-Sepharose beads (Pharmacia)]. Several other expression systems are available and may be employed to express fusion proteins comprising human Reg I γ (e.g., pMAL vectors from New England Biolabs, Beverly, MA).

25 IX. Assay For Human Reg I γ Activity

The ability of human Reg I γ to induce cell growth can be demonstrated using pancreatic islets isolated from rat pancreas. Freshly isolated islets are prepared as described by Unno *et al.* [(1992) in *Pancreatic Islet Cell Regeneration and Growth*, Vinik, ed., Plenum Press, NY, pp. 61-69] and are exposed in *in vitro* culture to recombinant human Reg I γ prepared as described
30 above. The growth-promoting activity of human Reg I γ can be demonstrated using methods well known to the art, including staining of untreated and treated islet samples to observe differences in cell division index. A higher cell cycle index indicates human Reg I γ has induced cell growth.

Alternatively, the treated and untreated islet samples may be cultured in the presence of radiolabeled thymidine to examine *de novo* DNA synthesis as described [Francis *et al.* (1992), *supra*]. An increase rate of DNA synthesis in the treated islets as compared to the untreated islets indicates human Reg I γ has induced cell growth.

5 An extension of these assays can be used to compare the cell division indices of biopsied cell samples and observing the difference in cell division index. A higher cell cycle index indicates that human Reg I γ has increased cell growth in the treated tissue. Alternatively, these assays may be employed to observe the therapeutic effect of administration of inhibitors of human Reg I γ ; inhibitors of human Reg I γ would lower the cell cycle index in treated tissues.

10 Human Reg I γ contains a number of amino acid residues which are conserved among the CRD of C-type lectins and therefore human Reg I γ may bind carbohydrates. The ability of recombinant human Reg I γ to bind carbohydrates may be demonstrated by examining the ability of human Reg I γ to bind to affinity columns comprising carbohydrates (*e.g.*, lactose, maltose, D-mannose, D-galactose, etc. which are available from Sigma Chemical Corp., St. Louis, MO) or
15 by using the assay described by Christa *et al.* (1994), *supra*.

C-type lectins, including members of the reg/PSP gene family, are known to agglutinate bacteria. The ability of human Reg I γ to agglutinate bacteria is demonstrated using the assay described by Iovanna *et al.* [(1991), *supra*]. Briefly, bacteria (*e.g.*, *E. coli* strains KH802 or JM101) are grown at 37°C to stationary phase in L-broth. The bacteria are then collected by
20 centrifugation and washed in PBS. The washed bacteria are resuspended in PBS containing 0.5 mM CaCl₂ (PBS/CaCl₂) and are placed in the wells of microtiter plates at a concentration of approximately 5 x 10⁷ bacteria/200 μ l PBS/CaCl₂. Human Reg I γ is then added at a variety of concentrations (*e.g.*, 1 to 50 μ g/ml) and the presence of macroscopic aggregation is monitored following a 3 hour incubation at 25°C. Concanavalin A and albumin at 50 μ g/ml may be
25 employed as positive and negative controls, respectively.

X. Production Of Human Reg I γ Specific Antibodies

Human Reg I γ substantially purified using polyacrylamide gel electrophoresis (PAGE) (Sambrook, *supra*) is used to immunize suitable animals (*e.g.*, rabbits, hamsters, rats, mice, goats, sheep, etc.) and to produce antibodies using standard protocols (alternatively, recombinant human
30 Reg I γ fusion proteins may be purified by affinity or metal chelation chromatography and used to immunize animals). The amino acid sequence translated from human Reg I γ is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity and a

corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Analysis to select appropriate epitopes, such as those near the C-terminus or in hydrophilic regions is described by Ausubel FM *et al.* (*supra*).

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM *et al.*, *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Purified human Reg I γ (native or fusion proteins) may be used to generate antibodies which react specifically with the human Reg I γ protein. The production of both polyclonal and monoclonal antibodies utilize techniques standard to the art. Polyclonal antibodies contain a mixture of different types of antibodies that are specific for many different antigens present on the immunogen. Monoclonal antibodies contain a single species of antibody having a defined specificity.

Briefly, polyclonal antibodies are generated by immunization of a host animal with a purified protein. The serum of the immunized animal will contain antibodies directed against one or more epitopes of the injected protein. When rabbits are used for the production of polyclonal antibodies specific for human Reg I γ , 50 to 1000 μ g of purified human Reg I γ is mixed with complete Freund's adjuvant and administered subcutaneously (s.c.) to the rabbit. Typically, multiple s.c. injections, each containing a maximum volume of about 400 μ l are administered (up to 10 injections may be performed per animal). Alternatively, the immunogen may administered by intramuscular or intradermal injection. Four to six weeks following the initial or primary injection, secondary or booster injections are administered (these may utilize incomplete Freund's adjuvant). Additional boosts are given in 4-6 week intervals following the last injection. Immunized rabbits are bled (*e.g.*, using the marginal ear vein) and the serum is screened for the presence of antibodies which react specifically with human Reg I γ (*e.g.*, by ELISA screening).

Immunization of mice is conducted as described above with the exception that the dose of antigen is 10-50 μ g per injection (250 μ l antigen solution mixed with 250 μ l complete Freund's adjuvant) and injection is given intraperitoneally (i.p.). The first boost is given two weeks later and employs incomplete Freund's adjuvant; subsequent boosts are given at about 3 week

intervals. Serum is collected from the immunized mice (e.g., by tail bleeding) and is screened for the presence of antibodies which react specifically with human Reg I γ (e.g., by ELISA screening).

Monoclonal antibodies are produced by immunizing a host animal with purified human
5 Reg I γ protein (native or fusion). Once the host has produced antibodies specific for human Reg I γ protein, the spleen of the host is removed. The plasma cells present in the spleen of the immune host are then fused with a myeloma cell (the "fusion partner") to produce hybridoma cells. When mice are immunized for the production of plasma cells to be used to generate hybridomas, suitable fusion partners include the X63Ag8.653, Sp2/0-Ag14, FO, NSI/1-Ag4-1,
10 NSO/1 and FOX-NY cell lines [*Antibodies: A Laboratory Manual*, Harlow and Lane, Eds. (1988) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p. 144]. When rats are immunized for the production of plasma cells to be used to generate hybridomas, suitable fusion partners include the YB2/0 and IR983F cell lines (Harlow and Lane, *supra*). Mice or rats are immunized as described above. Following the generation of specific anti-human Reg I γ
15 antibodies in the animals (typically following 2 to 3 booster injection and about 56 days following the initial injection), spleens are removed and splenocytes are fused (e.g., using polyethylene glycol) with the desired fusion partner. The fused cells are diluted in the appropriate selective medium and plated in multiwell culture plates. Each hybridoma cell produces a single type of antibody. Culture supernatant from individual hybridoma cells
20 (removed from the hybridomas about 1 week following plating) is screened using standard techniques to identify those hybridoma cells expressing monoclonal antibodies reactive with human Reg I γ (*see* Harlow and Lane, *supra* for a review of screening techniques).

When a fusion protein is utilized for the production of antibodies, the resulting antibodies may contain antibodies directed against the fusion partner (e.g., GST). These anti-fusion partner
25 antibodies may be removed from a polyclonal sera by chromatography of the sera on a column containing the fusion partner immobilized to a solid support such as Sepharose beads (Pharmacia). For example, to remove anti-GST antibodies from a polyclonal sera raised against a GST fusion protein, the sera is chromatographed on a resin comprising the GST protein covalently linked to glutathione Sepharose. Anti-fusion partner antibodies may be excluded
30 during the routine screening of hybridomas during the production of monoclonal antibodies.

XI. Purification Of Naturally Occurring Human Reg I γ Using Specific Antibodies

Naturally occurring or recombinant human Reg I γ is substantially purified by immunoaffinity chromatography using antibodies specific for human Reg I γ . An immunoaffinity column is constructed by covalently coupling human Reg I γ antibody to an activated chromatographic resin such as CnBr-activated Sepharose (Pharmacia Biotech). After the
5 coupling, the resin is blocked and washed according to the manufacturer's instructions.

Extracts from cells expressing human Reg I γ are prepared by methods well known in the art (*e.g.*, disruption of fresh or frozen ovarian or pancreatic tissue followed by centrifugation to remove cellular debris). Alternatively, a recombinant human Reg I γ fragment containing an appropriate signal sequence (the native Reg I γ or a heterologous signal sequence may be
10 employed) may be secreted in useful quantity into the medium in which transfected cells are grown.

A human Reg I γ -containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of human Reg I γ (*e.g.*, high ionic strength buffers in the presence of detergent). The column is eluted under
15 conditions that disrupt antibody/human Reg I γ binding (*e.g.*, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and human Reg I γ is collected.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit
20 of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: INCYTE PHARMACEUTICALS, INC.
- (ii) TITLE OF THE INVENTION: NOVEL HUMAN REG PROTEIN
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: US
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) PCT APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Filed Herewith
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/729,103
 - (B) FILING DATE: 08-OCT-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0138 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 650-855-0555
 - (B) TELEFAX: 650-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 158 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: COLNFET02
 - (B) CLONE: 1310334

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Ala Ser Arg Ser Met Arg Leu Leu Leu Leu Ser Cys Leu Ala
 1           5           10           15
Lys Thr Gly Val Leu Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro
          20           25           30
Gly Trp Phe Tyr His Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu
          35           40           45
Arg Asn Trp Ser Asp Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly
          50           55           60
Ala His Leu Ala Ser Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala
65           70           75           80
Glu Tyr Ile Ser Gly Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu
          85           90           95
His Asp Pro Gln Lys Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met
          100          105          110
Tyr Leu Tyr Arg Ser Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His
          115          120          125
Cys Ala Glu Met Ser Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn
          130          135          140
Glu Cys Asn Lys Arg Gln His Phe Leu Cys Lys Tyr Arg Pro
145          150          155

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 614 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: COLNFET02
- (B) CLONE: 1310334

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

TGAAGAAGGC AGGGGCCCTT AGAGTCTTGG TTGCCAAACA GATTTCGAGA TCAAGGAGAA      60
CCCAGGAGTT TCAAAGAAGC GCTAGTAAGG TCTCTGAGAT CCTTGCACTA GCTACATCCT      120
CAGGGTAGGA GGAAGATGGC TTCCAGAAGC ATGCGGCTGC TCCTATTGCT GAGCTGCCCTG      180
GCCAAAACAG GAGTCCTGGG TGATATCATC ATGAGACCCA GCTGTGCTCC TGGATGGTTT      240
TACCACAAGT CCAATTGCTA TGGTTACTTC AGGAAGCTGA GGAAGTGGTC TGATGCCGAG      300
CTCGAGTGTC AGTCTTACGG AAACGGAGCC CACCTGGCAT CTATCCTGAG TTAAAGGAA      360
GCCAGCACCA TAGCAGAGTA CATAAGTGGC TATCAGAGAA GCCAGCCGAT ATGGATTGGC      420
CTGCACGACC CACAGAAGAG GCAGCAGTGG CAGTGGATTG ATGGGGCCAT GTATCTGTAC      480
AGATCCTGGT CTGGCAAGTC CATGGGTGGG AACAAGCACT GTGCTGAGAT GAGCTCCAAT      540
AACAACTTT TAACCTGGAG CAGCAACGAA TGCAACAAGC GCCAACACTT CCTGTGCAAG      600
TACCGACCAT AGAG

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 165 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 393209

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Thr Arg Asn Lys Tyr Phe Ile Leu Leu Ser Cys Leu Met Val Leu
 1          5          10          15
Ser Pro Ser Gln Gly Gln Glu Ala Glu Glu Asp Leu Pro Ser Ala Arg
          20          25          30
Ile Thr Cys Pro Glu Gly Ser Asn Ala Tyr Ser Ser Tyr Cys Tyr Tyr
          35          40          45
Phe Met Glu Asp His Leu Ser Trp Ala Glu Ala Asp Leu Phe Cys Gln
          50          55          60
Asn Met Asn Ser Gly Tyr Leu Val Ser Val Leu Ser Gln Ala Glu Gly
          65          70          75          80
Asn Phe Leu Ala Ser Leu Ile Lys Glu Ser Gly Thr Thr Ala Ala Asn
          85          90          95
Val Trp Ile Gly Leu His Asp Pro Lys Asn Asn Arg Arg Trp His Trp
          100          105          110
Ser Ser Gly Ser Leu Phe Leu Tyr Lys Ser Trp Asp Thr Gly Tyr Pro
          115          120          125
Asn Asn Ser Asn Arg Gly Tyr Cys Val Ser Val Thr Ser Asn Ser Gly
          130          135          140
Tyr Lys Lys Trp Arg Asp Asn Ser Cys Asp Ala Gln Leu Ser Phe Val
          145          150          155          160
Cys Lys Phe Lys Ala
          165

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 474306

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ala Gln Thr Asn Ser Phe Phe Met Leu Ile Ser Ser Leu Met Phe
 1          5          10          15
Leu Ser Leu Ser Gln Gly Gln Glu Ser Gln Thr Glu Leu Pro Asn Pro
          20          25          30
Arg Ile Ser Cys Pro Glu Gly Thr Asn Ala Tyr Arg Ser Tyr Cys Tyr
          35          40          45
Tyr Phe Asn Glu Asp Pro Glu Thr Trp Val Asp Ala Asp Leu Tyr Cys
          50          55          60
Gln Asn Met Asn Ser Gly Asn Leu Val Ser Val Leu Thr Gln Ala Glu
          65          70          75          80
Gly Ala Phe Val Ala Ser Leu Ile Lys Glu Ser Ser Thr Asp Asp Ser
          85          90          95
Asn Val Trp Ile Gly Leu His Asp Pro Lys Lys Asn Arg Arg Trp His
          100          105          110
Trp Ser Ser Gly Ser Leu Val Ser Tyr Lys Ser Trp Asp Thr Gly Ser
          115          120          125

```

Pro	Ser	Ser	Ala	Asn	Ala	Gly	Tyr	Cys	Ala	Ser	Leu	Thr	Ser	Cys	Ser
	130					135					140				
Gly	Phe	Lys	Lys	Trp	Lys	Asp	Glu	Ser	Cys	Glu	Lys	Lys	Phe	Ser	Phe
145					150					155					160
Val	Cys	Lys	Phe	Lys	Asn										
				165											

CLAIMS

1. A substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1.
2. The polypeptide of Claim 1, wherein said purified polypeptide comprises a portion of
5 said SEQ ID NO:1 having a length greater than 10 amino acid residues.
3. An isolated polynucleotide sequence encoding the polypeptide of Claim 1.
4. The polynucleotide sequence of Claim 3 comprising at least a portion of the nucleic acid sequence of SEQ ID NO:2 or variants thereof.
5. The polynucleotide sequence of Claim 4, wherein said portion of said polynucleotide
10 comprises fragments of SEQ ID NO:2 having a length greater than 30 nucleotides.
6. The polynucleotide sequence of Claim 4 comprising the complement of the nucleic acid sequence of SEQ ID NO:2 or variants thereof.
7. A polynucleotide sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO:2.
- 15 8. A method for detecting the presence of polynucleotide sequences encoding at least a portion of human Reg I γ in a biological sample, comprising the steps of:
 - a) providing:
 - i) a biological sample suspected of containing nucleic acid corresponding
to the polynucleotide sequence of SEQ ID NO:2;
 - 20 ii) the polynucleotide of SEQ ID NO:2, or a fragment thereof;
 - b) combining said biological sample with said polynucleotide under conditions such that a hybridization complex is formed between said nucleic acid and said polynucleotide,
and
 - c) detecting said hybridization complex.
- 25 9. The method of Claim 8, wherein, said nucleic acid corresponding to the polynucleotide sequence of SEQ ID NO:2 is ribonucleic acid.
10. The method of Claim 9, wherein said detected hybridization complex correlates with expression of the polynucleotide of SEQ ID NO:2 in said biological sample.
11. The method of Claim 8, wherein, said nucleic acid corresponding to the
30 polynucleotide sequence of SEQ ID NO:2 is deoxyribonucleic acid.

12. The method of Claim 11, wherein said detecting of said hybridization complex comprises conditions that permit the detection of alterations in the polynucleotide of SEQ ID NO:2 in said biological sample.

13. An antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of SEQ ID NO:2.

14. A pharmaceutical composition comprising the antisense molecule of Claim 13 and a pharmaceutically acceptable excipient.

15. The polynucleotide sequence of Claim 4, wherein said polynucleotide sequence is contained on a recombinant expression vector.

16. The polynucleotide sequence of Claim 15, wherein said expression vector containing said polynucleotide sequence is contained within a host cell.

17. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, the method comprising the steps of:

a) culturing the host cell of Claim 16 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

18. A pharmaceutical composition comprising a substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable excipient.

19. A purified antibody which binds specifically to the polypeptide of Claim 1.

20. A pharmaceutical composition comprising the antibody of Claim 19 and a pharmaceutically acceptable excipient.

21. A method for detecting the expression of human Reg I γ in a biological sample comprising the steps of:

a) providing:

i) a biological sample suspected of expressing human Reg I γ protein; and

ii) the antibody of Claim 19;

b) combining said biological sample and said antibody under conditions such that an antibody:protein complex is formed; and

c) detecting said complex wherein the presence of said complex correlates with the expression of said protein in said biological sample.

```

      9      18      27      36      45      54
5' TGA AGA AGG CAG GGG CCC TTA GAG TCT TGG TTG CCA AAC AGA TTT GCA GAT CAA

      63      72      81      90      99      108
GGA GAA CCC AGG AGT TTC AAA GAA GCG CTA GTA AGG TCT CTG AGA TCC TTG CAC

      117      126      135      144      153      162
TAG CTA CAT CCT CAG GGT AGG AGG AAG ATG GCT TCC AGA AGC ATG CGG CTG CTC
      M A S R S M R L L

      171      180      189      198      207      216
CTA TTG CTG AGC TGC CTG GCC AAA ACA GGA GTC CTG GGT GAT ATC ATC ATG AGA
L L L S C L A K T G V L G D I I M R

      225      234      243      252      261      270
CCC AGC TGT GCT CCT GGA TGG TTT TAC CAC AAG TCC AAT TGC TAT GGT TAC TTC
P S C A P G G W F Y H K S N C Y G Y F

      279      288      297      306      315      324
AGG AAG CTG AGG AAC TGG TCT GAT GCC GAG CTC GAG TGT CAG TCT TAC GGA AAC
R K L R N W S D A E L E C Q S Y G N

      333      342      351      360      369      378
GGA GCC CAC CTG GCA TCT ATC CTG AGT TTA AAG GAA GCC AGC ACC ATA GCA GAG
G A H L A S I L S L K E A S T I A E

```

FIGURE 1A

2/7

387 396 405 414 423 432
TAC ATA AGT GGC TAT CAG AGA AGC CAG CCG ATA TGG ATT GGC CTG CAC GAC CCA
Y I S G Y Q R S Q P I W I G L H D P

441 450 459 468 477 486
CAG AAG AGG CAG CAG TGG CAG TGG ATT GAT GGG GCC ATG TAT CTG TAC AGA TCC
Q K R Q Q W Q Q W I D G A M Y L Y R S

495 504 513 522 531 540
TGG TCT GGC AAG TCC ATG GGT GGG AAC AAG CAC CAC TGT GCT GAG ATG AGC TCC AAT
W S G K K S M G G N K H C A E M S S N

549 558 567 576 585 594
AAC AAC TTT TTA ACT TGG AGC AGC AAC GAA TGC AAC AAG CGC CAA CAC TTC CTG
N N F L T W S S N E C N K R Q H F L

603 612
TGC AAG TAC CGA CCA TAG AG 3'
C K Y R P *

FIGURE 1B

1	M	A	S	R	S	M	R	L	L	L	L	S	C	L	-	-	-	A	K	T	G	V	L	G	D	I	I	M	-	-	-	R	P	S	C	A	P	G	1310334		
1	M	A	-	Q	T	N	S	F	F	M	L	I	S	S	L	M	F	L	S	L	S	Q	G	Q	E	S	Q	T	E	L	P	N	P	R	I	S	C	P	E	G	GI 474306
1	M	T	-	R	-	N	K	Y	F	I	L	L	S	C	L	M	V	L	S	P	S	Q	G	Q	E	A	E	E	D	L	P	S	A	R	I	T	C	P	E	G	GI 393209
34	W	F	Y	H	K	S	N	C	Y	G	Y	F	R	K	L	R	N	W	S	D	A	E	L	E	C	Q	S	Y	G	N	G	A	H	L	A	S	I	L	S	L	1310334
40	T	N	A	Y	R	S	Y	C	Y	Y	F	N	E	D	P	E	T	W	V	D	A	D	L	Y	C	Q	N	M	N	S	G	-	N	L	V	S	V	L	T	Q	GI 474306
39	S	N	A	Y	S	S	Y	C	Y	Y	F	M	E	D	H	L	S	W	A	E	A	D	L	F	C	Q	N	M	N	S	G	-	Y	L	V	S	V	L	S	Q	GI 393209
74	K	E	A	S	T	I	A	E	Y	I	S	G	Y	Q	R	S	Q	P	-	I	W	I	G	L	H	D	P	Q	K	R	Q	Q	W	I	D	G	A	M	1310334		
79	A	E	G	A	F	V	A	S	L	I	K	E	S	S	T	D	D	S	N	V	W	I	G	L	H	D	P	K	K	N	R	R	W	H	W	S	S	G	S	L	GI 474306
78	A	E	G	N	F	L	A	S	L	I	K	E	S	G	T	T	A	A	N	V	W	I	G	L	H	D	P	K	N	N	R	R	W	H	W	S	S	G	S	L	GI 393209
113	Y	L	Y	R	S	W	S	G	K	S	M	G	G	N	K	H	-	-	C	A	E	M	S	S	N	N	N	F	L	T	W	S	S	N	E	C	N	K	R	Q	1310334
119	V	S	Y	K	S	W	D	T	G	S	P	S	S	A	N	A	G	Y	C	A	S	L	T	S	C	S	G	F	K	K	W	K	D	E	S	C	E	K	K	F	GI 474306
118	F	L	Y	K	S	W	D	T	G	Y	P	N	N	S	N	R	G	Y	C	V	S	V	T	S	N	S	G	Y	K	K	W	R	D	N	S	C	D	A	Q	L	GI 393209
151	H	F	L	C	K	Y	R	P	1310334																																
159	S	F	V	C	K	F	K	N	GI 474306																																
158	S	F	V	C	K	F	K	A	GI 393209																																

FIGURE 2

4/7

Library	Lib Description	Abun	Pct Abun
<u>OVARNOT03</u>	ovary, 43 F, match to OVARUT01	<u>5</u>	0.1932
<u>OVARUT01</u>	ovarian tumor, 43 F, match to OVARNOT03	<u>3</u>	0.0968
<u>COLNNOT05</u>	colon, 40 M, match to PANCUT01	<u>2</u>	0.0577
<u>PANCNOT08</u>	pancreas, 65 F, match to PANCUT01	<u>1</u>	0.0254
<u>COLNFET02</u>	colon, fetal F	<u>1</u>	0.0142

FIGURE 3

5/7




FIGURE 4

6/7




FIGURE 5

	10	20	30	40	50	60	70
	MASRSMRLLLLSCLAKTGLGDIIMRPSCAPGWFYHKSNICYGFRKLRNWSDAELECQSYGNGAHLASI						
HELIX	hhhhhhhhhh				HHHHHHHHHh	hhhhhh	
SHEET	ssssssssssssssssss		sss	ssss	sss	ssss	
TURN	TTTTT		TTTTTTTTT	TTTTTTTTT	TTTT	TTTTTTTTT	
COIL	C						
	80	90	100	110	120	130	140
	LSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQOWIDGAMYLYRSWSGKSMGGNKHCAEMSSNNNFLT						
HELIX	hhHHHHHHhh	hhhhhh	hhHHHHHHHHH			hhHHh	
SHEET	SSS	SSSSs	ssssssssssssssssss				sss
TURN		TTTTTTTTT	TTTT		TTTTTTTTTTTTT	TTTTTTTTT	
COIL							
	150						
	WSSNECNKRQHFLCKYRP						
HELIX		hhhhhh					
SHEET	s	ssssss					
TURN	TTTTTTTTTTTTT						
COIL							CC

FIGURE 6

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/18174

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 A61K38/17 C12N15/11 A61K31/70
C12N1/21 C12N15/62 C07K19/00 C12Q1/68 G01N33/50
G01N33/60 C07K16/28 G01N33/53 A61K39/395 //(C12N1/21,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 96 39541 A (HUMAN GENOME SCIENCES INC ;SOPPET DANIEL R (US); LI YI (US); DILLO) 12 December 1996 see page 3, paragraph 4 - page 21, paragraph 2 see page 28, paragraph 3 - page 39, paragraph 4 see page 51 - page 57; claims</p> <p style="text-align: center;">-/-</p>	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

13/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18174

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAKUO WATANABE ET AL.: "Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The REG protein, Pancreatic Stone Protein, and Pancreatic Thread Protein are one and the same product of the gene" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 13, 5 May 1990, pages 7432-7439, XP000126179 cited in the application	
A	UNNO M. ET AL.: "Structure, chromosomal localization, and expression of mouse reg genes, reg I and reg II" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 21, 25 July 1993, pages 15974-15982, XP002053455 cited in the application	

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "G" document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18174

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>Database EMBL, entry HSZZ19915, Accession number AA314779. 18.April.1997. XP002053456 see the whole document</p> <p>-----</p>	1-7

Information on patent family members

PCT/US 97/18174

Form PCT/ISA/210 (patent family annex) (July 1992)